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Abstract 
 
Rationale: The profile of acquisition for MDMA self-administration differs from that 
of amphetamine and cocaine self-administration in that fewer rats meet an acquisition 
criterion and the latency to acquisition is longer. These characteristics of MDMA self-
administration may be because it preferentially stimulates serotonin (5HT) release 
whereas self-administration has generally been attributed to enhanced dopamine (DA) 
neurotransmission. Because 5HTergic agonists are not self-administered and 
increased synaptic 5HT decreased self-administration of other drugs, MDMA self-
administration may be initially inhibited by the pronounced 5HT response. 
Accordingly, the acquisition of MDMA self-administration might proceed as a result 
of deficits in 5HT neurotransmission and a corresponding disinhibition of DA 
neurotransmission.   
Objective: The primary objective was to determine the role of 5HT in the acquisition 
and maintenance of MDMA self-administration.  
Methods: MDMA-induced increases of extracellular 5HT and DA and their primary 
metabolites were measured in the DA terminal regions of the nucleus accumbens 
(NAc) using in vivo microdialysis, prior to the commencement of MDMA self-
administration. The relationship between MDMA-induced increases of 
neurotransmitter levels and the acquisition of MDMA self-administration was 
assessed. A subsequent study depleted brain 5HT by administering the neurotoxin, 5,7 
– DHT, or vehicle into the lateral ventricle of the left hemisphere, prior to the 
commencement of MDMA self-administration. The proportion of subjects that 
acquired MDMA self-administration and the latency to acquire MDMA self-
administration was compared for the two groups. In order to determine effects of 
MDMA self-administration on 5HT and DA responses, behaviours that reflect 5HT 
and/or DA neurotransmission  were measured 5 or 14 days after self-administration of 
165 mg/kg MDMA, or 14 days after vehicle self-administration. These time periods 
were chosen because they reflect a period of 5HT deficits (5 days) and recovery (14 
days). Finally, the effect of abstinence on MDMA self-administration was measured.  
Results: The MDMA-induced increase of extracellular 5HT was significantly lower 
for the group that subsequently acquired MDMA self-administration but the MDMA-
induced increase in DA was not different from the group that failed to acquire self-
administration. 5, 7-DHT administration significantly decreased tissue levels of 5HT, 
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but not DA. MDMA self-administration was facilitated by the lesion; 100% of the 
lesion group acquired MDMA self-administration, whereas only 50% of the control 
group acquired self-administration. Five days following the last MDMA self-
administration session, DAergic behaviours were enhanced and 5HTergic behaviours 
were reduced relative to the control group. These differences in 5HTergic mediated 
behaviours were not apparent 14 days after self-administration but the DAergic 
behaviours remained elevated. The pattern of self-administration did not differ as a 
function of the length of the abstinence period. 
Conclusions: The variability in acquisition of MDMA self-administration was related 
to the magnitude of the 5HT response evoked by initial exposure to MDMA. These 
findings suggested that predisposing differences in the 5HT response might explain 
differences in the variability in acquisition of MDMA self-administration. The 
negative impact of 5HT on the acquisition of MDMA self-administration was clearly 
demonstrated following a 5, 7-DHT lesion. Thus, 5HT limits the development of 
MDMA self-administration. With repeated exposure to self-administered MDMA, 
behavioural responses indicative of 5HT activation were reduced whereas behavioural 
indices of DA activation were increased. The maintenance of MDMA self-
administration was comparable regardless of whether there was a forced abstinence 
period or not. These data are consistent with the hypotheses that 5HT is inhibitory to 
the acquisition, but not the maintenance, of MDMA self-administration. Rather, the 
maintenance of self-administration might reflect sensitised DA responses that became 
apparent following repeated exposure.   
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General Introduction 
 
History of MDMA 
The pharmaceutical company, Merck, first synthesised 3, 4- 
methylenedioxymethamphetamine (MDMA) while attempting to create a medication 
to stop bleeding. Merck applied for the patent of MDMA as an intermediate chemical 
in the synthesis of the styptic, hydrastinine, in December 1912. Until 1953, MDMA 
was mentioned only twice in scientific literature and only as a by-product of chemical 
reactions (Swarts, 2006). After that the U.S. Army Chemical Center funded the testing 
of MDMA on 5 animal species: mice, rats, guinea pigs, dogs and monkeys (Hardman, 
Haavik, & Seevers, 1973). In 1975, MDMA was classified as a Class A drug under 
the Misuse of Drugs Regulation (1975) in the United Kingdom because it was 
considered to have no medicinal use (Advisory on the Misuse of Drugs, 2009).  
The first report of the effects of MDMA was published by Shulgin and 
Nichols (1978). Shulgin synthesised MDMA in 1976 and recorded his experiences 
following consumption of the drug. MDMA induced an “easily controlled altered 
state of consciousness, with emotional and sensual overtones”(Shulgin, 1986; p 299), 
and he therefore recommended the drug for use as an adjunct to psychotherapy. The 
use of MDMA in this capacity was not highly publicised (as LSD had recently been 
scheduled and thus removed from therapeutic practice (E. Greer, 1985). Recreational 
use of MDMA in the U.S.A. increased in the early 1980s and became controlled as a 
Schedule I substance in 1985. Drugs classified as Schedule I are described as having 
high abuse potential, and as having no accepted use for clinical application (The 
United States Department of Justice, 2008).  
 
Prevalence of use  
MDMA is the primary psychoactive component of the street drug, Ecstasy. 
According to the (World Drug Report, 2013) ecstasy use has declined, with an 
estimated 0.2 - 0.6% of the population having taken ecstasy annually since 2011. 
Other surveys have reported increases in ecstasy use. The latest Monitoring the Future 
survey reported that ecstasy use in U.S. college students aged between 15 and 18 has 
increased from, between 2.6-3% in 2005, to between 3.6- 4% in 2013 (Johnston, 
O'Malley, Miech, Bachman, & Schulenberg, 2014). Ecstasy use in Oceania continues 
to be highest with 2.9% of the population having consumed it in 2011. In New 
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Zealand, ecstasy is the second most widely used illegal drug, and the number of 
seizures rose markedly in 2011 (Wilkins & Sweetsur, 2008). Further, frequent users 
of ecstasy in NZ perceive the drug to be “easy” to obtain, and the mean price of pills 
has decreased since 2006 (Wilkins, Sweetsur, Smart, Warne, & Jawalkar, 2012).  
The pattern of ecstasy use differs from that of other drugs of abuse in that 
many users consume ecstasy sporadically and fail to exhibit the compulsive use that 
characterises abuse (Solowij, Hall, & Lee, 1992). Some surveys, however, indicate 
that the frequency of use increases over time for some users (Degenhardt, Barker, & 
Topp, 2004; Fox, Parrott, & Turner, 2001; George, Kinner, Bruno, Degenhardt, & 
Dunn, 2010; Scholey et al., 2004; Soar, Turner, & Parrott, 2006) and that some users 
meet the criteria for dependence and/or abuse (Cottler, Womack, Compton, & 
Ben‐Abdallah, 2001; Degenhardt et al., 2009; Leung, Ben Abdallah, Copeland, & 
Cottler, 2010; von Sydow, Lieb, Pfister, Höfler, & Wittchen, 2002), including craving 
and drug-seeking (Hopper et al., 2006). 
 
Pharmacology of MDMA  
The primary neurochemical effect of MDMA is to increase the release of the 
neurotransmitter, serotonin (5HT). MDMA was first reported to induce the release of 
5HT after the observation that both stereoisomers of the drug released 3H-5HT from 
hippocampal slices (Johnson, Hoffman, & Nichols, 1986). Subsequent experiments 
determined that MDMA induced the release of 5HT via a carrier-mediated 
mechanism (Berger, Gu, & Azmitia, 1992; Gu & Azmitia, 1993; Gudelsky & Nash, 
1996; Hekmatpanah & Peroutka, 1990). 
MDMA causes the release of 5HT via two processes. First, MDMA binds to 
the 5HT transporter (SERT), and reverses the transport of 5HT across the neuronal 
membrane so that 5HT moves out of the neuron as MDMA moves into the neuron 
(Rudnick & Wall, 1992). Second, MDMA enters the neuron and reverses the action of 
the vesicular monoamine transporter (VMAT2). In 5HTergic nerve terminals, 
VMAT2 transports unbound cytosolic 5HT into vesicles (Rudnick & Wall, 1992). 
MDMA interferes with this system by binding to VMAT2 and consequently increases 
cytosolic 5HT via two means. First, the binding of MDMA to VMAT2 blocks 5HT 
from doing so and thus prevents cytosolic 5HT from being transported into vesicles. 
Second, the binding of MDMA to VMAT2 results in the influx of MDMA into 
vesicles and concurrently, the efflux of vesicular 5HT to the cytosol. Additionally, 
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MDMA increases cytosolic 5HT by inhibiting its metabolism. MDMA inhibits the 
metabolising enzyme, monoamine oxidase (MAO; Leonardi & Azmitia, 1994). The 
interactions of MDMA with VMAT2 and MAO increase cytosolic 5HT and lead to a 
greater amount of 5HT being released through the reversed SERT into the synapse.  
Like all other drugs of abuse, MDMA increases extracellular levels of 
dopamine (DA). MDMA induces the dose- and region- dependent release of DA as 
shown in vivo, as measured by microdialysis, and in vitro, as measured in tissue slices 
(Gough, Ali, Slikker Jr, & Holson, 1991; Johnson et al., 1986; Schmidt, 1987; B. K. 
Yamamoto & Spanos, 1988).  
The increase in DA is due to decreased uptake due to inhibition of the DA 
transporter (DAT): DAT inhibitors prevented MDMA-induced increases in DA 
following local administration in vivo (Nash & Brodkin, 1991), or in brain slices 
(Koch & Galloway, 1997), or synaptosomes (Crespi, Mennini, & Gobbi, 1997). The 
affinity for DAT is at least 10-fold less than affinity for the SERT (Battaglia, Brooks, 
Kulsakdinun, & De Souza, 1988), which might explain why MDMA-produced 
increases in 5HT are so much greater than increases of DA. A summary of the 
microdialysis studies that measured MDMA-induced increases of synaptic 5HT and 
DA can be found in Schenk (2011), where table 1 shows conclusively that MDMA 
increases extracellular 5HT to a much greater extent than it does extracellular DA. For 
example, MDMA(1.5 mg/kg) administered into the peritoneum increased accumbal 
5HT by 500%, but had no effect on DA. At the higher dose of 7.5 mg/kg, MDMA 
increased 5HT by 3000% and DA by 500% (Baumann, Clark, & Rothman, 2008). 
Because MDMA preferentially increases 5HT, the possibility that 5HT release 
impacts induced DA release has been investigated. The data indicate that the 
relationship between 5HT and DA neurotransmission is complicated, and the effects 
depend on the 5HT receptor systems stimulated. Many 5HT receptors are localised on 
DA terminals (Bubar, Stutz, & Cunningham, 2011; Miner, Backstrom, Sanders-Bush, 
& Sesack, 2003; Nayak, Rondé, Spier, Lummis, & Nichols, 2000) and antagonists of 
the 5HT1A, 5HT1B and 5HT2 receptors have all been shown to increase endogenous 
levels of DA (Navailles & De Deurwaerdère, 2011). A handful of studies has 
investigated the role of the 5HT2A receptor in MDMA-produced DA release. The 
selective 5HT2A receptor antagonist, MDL 100907, and the 5HT2A/2C antagonists, 
ritanserin and ketanserin, blocked MDMA-induced increases of synaptic DA (Nash, 
1990; Schmidt, Fadayel, Sullivan, & Taylor, 1992; Schmidt, Sullivan, & Fedayal, 
12 
 
1994; B. K. Yamamoto, Nash, & Gudelsky, 1995). In contrast, the 5HT2A agonists, 
DOI and 5-MeODMT enhanced MDMA-induced DA release (Gudelsky, Yamamoto, 
& Nash, 1994). MDMA-induced increases of DA, therefore, are mediated by 
MDMA-induced 5HT release via specific receptor activation. These receptor-
mediated effects might also explain why administration of the 5HT precursor, 5-
hydroxytryptophan, potentiated MDMA-induced DA release (Gudelsky & Nash, 
1996); and why the inhibition of MDMA-induced 5HT release via administration of 
the SERT uptake inhibitor, fluoxetine (Gudelsky & Nash, 1996), or the global 
depletion of 5HT induced by the 5HT synthesis inhibitor, pCPA (Brodkin, Malyala, & 
Frank Nash, 1993), decreased MDMA-produced striatal DA release. Irrespective of 
the specific mechanism, these data support the idea that at least part of the effect of 
MDMA on DA is indirect and requires 5HT. 
 
Effects of Ecstasy 
Recreational users report that the euphoria produced by ecstasy entices them 
to take it (Cohen, 1995; Solowij et al., 1992). Other commonly reported positive 
psychological effects include increased energy, sexual arousal, well-being and self-
confidence, and an enhanced feeling of closeness to others (Cohen, 1995; Downing, 
1986; G. Greer & Tolbert, 1986; Peroutka, Newman, & Harris, 1988; Solowij et al., 
1992). MDMA also produces negative effects, including depression, anxiety and 
paranoia (Cohen, 1995).  
There are long-term psychological and physiological effects even following a 
single ingestion of ecstasy. These include depersonalisation, insomnia, depression, 
frequent headaches, back and stomach pain and joint stiffness (Cohen, 1995). 
Memory deficits (Fisk, Montgomery, & Hadjiefthyvoulou, 2011), and compromised 
executive functioning  and reasoning abilities (Fisk, Montgomery, Wareing, & 
Murphy, 2005; von Geusau, Stalenhoef, Huizinga, Snel, & Ridderinkhof, 2004) have 
also been reported. These impairments are persistent and have been reported even 
after years of abstinence (M. Morgan, McFie, Fleetwood, & Robinson, 2002; Taurah, 
Chandler, & Sanders, 2013) 
The long-term psychological and cognitive effects of ecstasy use may be due 
to the persistence of neuroadaptations and deficits in 5HT neurotransmission that are 
characteristic of ecstasy users (Cowan, Roberts, & Joers, 2008). There were increased 
levels of the 5HT precursor, tryptophan, following a tryptophan drink in ecstasy users 
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that had been abstinent for at least one year (Curran & Verheyden, 2003). SERT 
availability, as measured by positron emission topography (PET), was decreased in 
current ecstasy users (Buchert et al., 2004) and SERT density, as measured by PET, 
was decreased in users that had been abstinent for 2 or 3 weeks (McCann, Szabo, 
Scheffel, Dannals, & Ricaurte, 1998; McCann et al., 2008). Ecstasy-produced changes 
in SERT appear to depend on life-time use of ecstasy and the frequency with which it 
was consumed. Recreational users, who averaged using ecstasy 3 times every 2 
months, did not exhibit alterations of SERT as measured by endocrine responses to 
the SERT uptake inhibitor, citalopram (Allott et al., 2009). SERT binding was, 
however, negatively related to life-time use of ecstasy and the maximum dose used 
(Kish et al., 2010; McCann et al., 1998; McCann et al., 2008). These decreases in 
SERT might not be persistent since SERT binding increased with abstinence from 
ecstasy (Buchert et al., 2004).  
Ecstasy use also appears to alter the binding characteristics of post-synaptic 
5HT receptors. Both PET and single photon emission computed tomography (SPECT) 
showed increased 5HT2A receptor binding in abstinent ecstasy users (Reneman, Booij, 
Schmand, van den Brink, & Gunning, 2000; Urban et al., 2012) that was positively 
related to life-time ecstasy use (Di Iorio et al., 2011). Ecstasy users also were less 
responsive to the neuroendocrine response, and showed fewer physical effects to the 
5HT2C agonist, mCPP (McCann, Eligulashvili, Mertl, Murphy, & Ricaurte, 1999). 
 
Interpretation of Clinical Data 
Reports of the effects of ecstasy provide invaluable information; however, 
interpretation of the clinical data is problematic for a number of reasons. Due to 
ethical considerations clinical data rely on retrospective studies using current or 
abstinent ecstasy users. It is therefore unclear whether reported effects were pre-
existing or due to drug use. Because there is no accurate information about the dose of 
MDMA taken, the number of times ecstasy was consumed, and the purity of the 
ecstasy used, it is difficult to attribute doses of MDMA to long-term effects of drug 
use (Green, Mechan, Elliott, O'Shea, & Colado, 2003). Further, polydrug use is 
common in ecstasy users and prevents the attribution of long-term effects of drug use 
to MDMA (Green et al., 2003). Animal models provide a means to control for these 
factors. 
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The Effects of MDMA on Tissue Levels of 5HT and DA 
MDMA produces deficits in 5HT and markers of 5HT but not other 
monoamines. In a seminal experiment, an acute, subcutaneous administration of 10.0 
mg/kg MDMA significantly decreased tissue levels of 5HT, tryptophan hydroxylase 
(TPH; the rate-limiting enzyme of 5HT synthesis), and 5-Hydroxyindoleacetic acid 
(5HIAA; the main metabolite of 5HT) in the neostriatum, hippocampus and frontal 
cortex (FC) 3 hours post drug administration (Stone, Stahl, Hanson, & Gibb, 1986). 
Subsequent experiments demonstrated that the MDMA-induced 5HTergic depletions 
were dose-dependent (Schmidt, Wu, & Lovenberg, 1986). 
There was recovery of 5HT depletions that was both dose- and time- 
dependent (Schmidt et al., 1986; Stone, Hanson, & Gibb, 1987). MDMA decreased 
5HT levels 3 hours after administration. This depletion was still present up to 6 hours 
post-administration, but had recovered within 24 hours of MDMA administration. A 
second decline in tissue levels of 5HT was observed 1 day after drug administration 
and was still present 7 days (Schmidt et al., 1986), and 14 days  (Stone, Merchant, 
Hanson, & Gibb, 1987), later .  
MDMA administration produced an increase in tissue DA. In rats, tissue levels 
of DA were dose-dependently increased 1 (B. K. Yamamoto & Spanos, 1988), 2 (B. 
K. Yamamoto & Spanos, 1988), and 3 (Logan, Laverty, Sanderson, & Yee, 1988; 
Schmidt et al., 1986; Stone et al., 1986) hours after an acute administration of 
MDMA. That increased DA levels are found concurrently with 5HT deficits is in 
contrast to the effect of 5HT neurotransmission on extracellular levels of DA. The 
increase may be a reflection of MDMA inhibiting the action of MAO, as the 
concentration of the DA metabolite, 3,4-Dihydroxyphenylacetic acid (DOPAC), was 
concurrently decreased (B. K. Yamamoto & Spanos, 1988).  
 
The Effects of Repeated MDMA on Tissue 5HT & DA 
Arguably the most consistent finding of effects of repeated exposure to 
MDMA is reduced tissue levels of 5HT.  Repeated exposure to MDMA produces 
species-dependent reductions in 5HT and markers of 5HT; dose-dependent 5HTergic 
deficits were observed in non-human primates and rats (Battaglia, Yeh, & De Souza, 
1988; Insel, Battaglia, Johannessen, Marra, & De Souza, 1989), but not mice 
(Battaglia, Yeh, et al., 1988; Stone, Hanson, et al., 1987). The frequency of MDMA 
administration also influences the magnitude of 5HT deficits. O'Shea, Granados, 
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Esteban, Colado, and Green (1998) measured 5HT deficits following administration 
of 4.0 mg/kg MDMA daily for 4 days, twice-weekly for 8 weeks, or twice daily for 4 
days. Only the latter dosing regimen decreased 5HT, suggesting that the cumulative 
effects of repeated administrations of MDMA caused deficits, and that dosing with 
lower frequency allows for recovery.  
A decrease in density of SERT binding sites was found only after repeated 
exposure to high doses of MDMA (Insel et al., 1989). In rats, a dosing regimen of 
20.0 mg/kg MDMA (sc) twice daily for 4 days, led to a decrease in the density of 
cortical and striatal 5HT uptake sites 18 hours after the final drug administration. 
SERT density was still decreased one month later, but had recovered 12 months after 
MDMA (Battaglia, Yeh, et al., 1988).  
The marked effects of MDMA on tissue levels of 5HT and SERT density have 
led to a debate as to whether the decreases are due to neuroadaptation, or to 
neurotoxicity that results in degeneration of 5HT terminals or neurons (Biezonski & 
Meyer, 2011). Decreased SERT density was initially considered an indication of 
neurotoxicity (for example, Battaglia, Brooks, et al., 1988). The decreases may, 
however, reflect a reduction in functional SERT. X. Wang, Baumann, Xu, Morales, 
and Rothman (2005) hypothesised that reported decreases of SERT binding were due 
to the internalisation of SERT, which reduced the number of functional SERT. 
MDMA did not, however, alter the distribution of SERT in subcellular fractions. It 
must be noted though, that the specificity of the SERT antibody has since been 
questioned (Kivell, Day, Bosch, Schenk, & Miller, 2010). Other data suggest MDMA 
causes the internalisation of SERT; prolonged exposure to MDMA induced SERT 
internalisation in cultured 5HT neurons (Kittler, Lau, & Schloss, 2010), and dose-
dependent internalisation of SERT was found in cell lines following MDMA 
treatment (Kivell et al., 2010). These studies suggest that, at least following some 
exposure regimens, the decrease in SERT binding is due to neuroadaptive changes- 
specifically, internalisation of SERT- rather than to neurotoxicity.  
Further evidence for a neuroadaptive rather than neurodegenerative response 
to MDMA has been found in studies that measured VMAT2. Located in the terminals, 
the protein can be measured as a marker of terminal degeneration. MDMA (4 x 10.0 
mg/kg with 1 hour between each administration) decreased SERT, but not VMAT2, 
expression in rats, as measured by immunoblotting (Biezonski & Meyer, 2011). 
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Doses of MDMA that cause the long-term reduction of 5HT and markers of 
the 5HT system do not cause long-term decreases in DA neurotransmission. Markers 
of DA (Colado & Green, 1994), the function of DAT (for example; Battaglia et al., 
1987; Lew et al., 1996; Schmidt & Kehne, 1990; Stone et al., 1986) and the fibre 
density of DAergic neurons (O'Hearn, Battaglia, De Souza, Kuhar, & Molliver, 1988) 
were not altered by repeated MDMA. Stringent dosing regimens that used extremely 
high doses of MDMA, however, seem to produce a transient decrease in tissue levels 
of DA and metabolites that is region-dependent (Biezonski et al., 2013; Commins et 
al., 1987; Slikker et al., 1988). 
 
Effects of Repeated MDMA on Extracellular 5HT and DA 
Repeated exposure to MDMA does not affect basal levels of extracellular 5HT 
(Gartside, McQuade, & Sharp, 1996; Reveron, Maier, & Duvauchelle, 2010; 
Shankaran & Gudelsky, 1999), but decreased both MDMA- (Shankaran & Gudelsky, 
1999) and electrical- (Gartside et al., 1996) stimulated release of 5HT.  
Repeated exposure to MDMA, whether self-administered or experimenter-
administered, did not alter basal levels of extracellular DA (Colussi-Mas, Wise, 
Howard, & Schenk, 2010; Kalivas, Duffy, & White, 1998; A. E. Morgan, Horan, 
Dewey, & Ashby Jr, 1997; Reveron et al., 2010). Few studies have measured the 
effects of repeated MDMA on the stimulated release of extracellular DA. Repeated 
exposure to MDMA augmented cocaine- (COC; A. E. Morgan et al., 1997) and 
MDMA- (Kalivas et al., 1998) induced increases in DA in the nucleus accumbens 
(NAc). A different dosing regimen, however, had no effect on MDMA-induced 
extracellular DA in the striatum (Shankaran & Gudelsky, 1999).  
 
Self-administration 
Data from animal research reports similar neurochemical effects to clinical 
reports. The laboratory studies, however, vary markedly in the doses of MDMA used 
and questions have been asked of whether these doses are relevant to human 
consumption. The translation of doses of drugs used by humans to drug doses used for 
animal research is complicated. A number of factors influence the scaling, including 
metabolism of drug, pharmacokinetics, animal size, and drug distribution, and as a 
result a number of calculations for translating doses have been offered (for example, 
Reagan-Shaw, Nihal, & Ahmad, 2008; United States Department of Health and 
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Human Services, 2005). In addition, it has been well established that the 
neurochemical effects of drugs differ depending on whether the drug is self- 
administered or is non-contingently administered (Dworkin, Mirkis, & Smith, 1995; 
Hemby, Koves, Smith, & Dworkin, 1997). Thus the neurochemical effects produced 
following human consumption can be expected to differ from those found in animals 
after experimenter-administered drug. A typical ecstasy tablet contains about 100 mg 
of MDMA, which equates to a dose of 1.4 mg/kg in a 70 kg person. The animal 
research described previously used much higher doses of MDMA, and therefore the 
translational value of these experiments is questionable. These dosing problems are 
minimised in the self-administration model, in which the animal regulates its intake.  
 
Self-Administration History 
In 1962 the development of the chronic indwelling intravenous catheter 
permitted studies of long-term drug self-administration in laboratory animals (Weeks, 
1962). Self-administration experiments have since been conducted in a number of 
species, namely: non-human primates (T. Thompson & Schuster, 1964; Yanagita, 
Deneau, & Seevers, 1963); rats (Weeks & Collins, 1964); mice (Hillman & 
Schneider, 1975); cats (Balster, Kilbey, & Ellinwood Jr, 1976); and dogs (Risner & 
Jones, 1975). 
The self-administration paradigm is considered the “gold-standard” animal 
model of human drug-taking behaviour. Most drugs that are abused by humans are 
self-administered by animals, and drugs that are not abused by humans are not self-
administered by animals (Griffiths, 1980; Johanson & Balster, 1978; Schuster & 
Thompson, 1969). As a result, self-administration procedures are considered valid 
tests of the abuse liability of novel compounds (Schuster & Johanson, 1974). 
 
The Role of DA in Self-administration 
A large number of studies has documented the critical role of DA in the 
positively reinforcing properties of drugs using self-administration measures. Early 
studies showed that DA ligands, but not norepinephrine (NE) ligands, considerably 
altered responding for amphetamine (AMPH; Yokel & Wise, 1976), and responding 
was maintained when DA receptor agonists were made available following the self-
administration of AMPH (Yokel & Wise, 1978).  
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All drugs of abuse share the characteristic of increasing DA (Di Chiara, 
Acquas, Tanda, & Cadoni, 1992) and drugs of abuse, but not non-abused drugs, 
increased extracellular levels of DA (Di Chiara & Imperato, 1988). Further, drug-
naïve animals self-administered DAergic agonists (Self, Belluzzi, Kossuth, & Stein, 
1996; Self & Stein, 1992; Weed & Woolverton, 1995) and COC-trained animals 
continued to respond when D1 and D2 receptor agonists were made available (Ranaldi, 
Wang, & Woolverton, 2001; Weed & Woolverton, 1995; Woolverton, Goldberg, & 
Ginos, 1984). Furthermore, co-administration of DA agonists shifted the dose-effect 
curve of responding for COC leftward (Barrett, Miller, Dohrmann, & Caine, 2004), 
comparable to what is found when the dose of COC is increased.  
The attenuation of DA neurotransmission retards self-administration of drugs 
of abuse. Neurotoxic 6-OHDA lesions that decreased DA levels attenuated 
responding maintained by AMPH (Lyness, Friedle, & Moore, 1979), COC (Caine & 
Koob, 1994a; D Roberts, Corcoran, & Fibiger, 1977; D Roberts & Koob, 1982), 
morphine (J. E. Smith, Guerin, Co, Barr, & Lane, 1985) and nicotine (Singer, 
Wallace, & Hall, 1982), whereas lesions that decreased NE had no effect (D Roberts 
et al., 1977). The lesions also inhibited the acquisition of AMPH self-administration 
(Lyness et al., 1979). 
A multitude of data now show that D1 and D2 antagonists decreased 
responding for, or caused a rightward shift in the dose-effect curve of responding for, 
drugs of abuse- comparable to what is found when the dose of drug is lowered. D1 
receptor antagonists decreased responding for methamphetamine (METH; Brennan, 
Carati, Lea, Fitzmaurice, & Schenk, 2009), and caused a rightward shift in the dose-
effect curve of responding for MDMA (Daniela, Brennan, Gittings, Hely, & Schenk, 
2004) and COC (Barrett et al., 2004; Britton et al., 1991; Caine & Koob, 1994a; 
Corrigall & Coen, 1991; Hubner & Moreton, 1991; Koob, Le, & Creese, 1987). D2 
receptor antagonists decreased responding for AMPH (Amit & Smith, 1992; Fletcher, 
1998) and caused a rightward shift of the dose-effect curve for MDMA (Brennan et 
al., 2009) and COC (Barrett et al., 2004; Britton et al., 1991; Caine & Koob, 1994a; 
Corrigall & Coen, 1991; Hubner & Moreton, 1991).  
Local infusion of drugs of abuse and DA ligands has identified the DA 
projections of the mesolimbic DA system to be critical to self-administration of drugs 
of abuse. 6-OHDA lesions of the ventral tegmental area (VTA), which contains the 
cell bodies of DA neurons that comprise the mesolimbic system decreased responding 
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maintained by COC (D Roberts & Koob, 1982). 6-OHDA lesions of the DA terminals 
in the NAc decreased responding maintained by COC, AMPH, morphine, nicotine 
and morphine (Caine & Koob, 1994b; Lyness et al., 1979; Pettit, Ettenberg, Bloom, & 
Koob, 1984; D Roberts et al., 1977; D Roberts, Koob, Klonoff, & Fibiger, 1980; 
Singer et al., 1982; J. E. Smith et al., 1985). Similarly, the localised infusion of D1 and 
D2 antagonists into the NAc attenuated responding for MDMA (Shin, Qin, Liu, & 
Ikemoto, 2008) or COC (Bari & Pierce, 2005; Veeneman, Broekhoven, Damsteegt, & 
Vanderschuren, 2012), and caused a rightward shift in the dose-effect curve of 
responding for COC (Caine, Heinrichs, Coffin, & Koob, 1995) or AMPH (Phillips, 
Robbins, & Everitt, 1994). Further evidence for the role of the NAc in drug-produced 
reinforcement is found with the acquisition of MDMA (Shin et al., 2008), COC 
(Rodd-Henricks, McKinzie, Li, Murphy, & McBride, 2002) and AMPH (Ikemoto, 
Qin, & Liu, 2005) self-administration when drug was infused directly into the NAc. 
The pattern of responding also appears to be DA-dependent. An elegant 
microdialysis study showed that the time-course of COC self-administration was 
tightly linked to NAc DA levels. Responding was rapid at the beginning of a COC 
self-administration session and NAc extracellular DA was increased. When DA levels 
dropped below a certain, threshold, level a response was produced (Pettit & Justice Jr, 
1989; Wise et al., 1995).  
 
The Role of 5HT in Self-administration 
There is conclusive evidence to show that 5HT is inhibitory to self-
administration of drugs of abuse. It has been suggested that this inhibition is due to 
manipulation of DA (Czoty, Ginsburg, & Howell, 2002), but the data is inconclusive 
due to the complicated relationship between the two neurotransmitter systems. 
Serotonergic agonists are not self-administered (Götestam & Andersson, 1975; 
Howell & Byrd, 1995; D Roberts et al., 1999; Tessel & Woods, 1975; Vanover, 
Nader, & Woolverton, 1992). The DAT is the primary mechanism for limiting DA 
transmission (Caron, 1996), and has been implicated in the propensity to self-
administer drugs of abuse (D. Yamamoto et al., 2013). Binding affinity at SERT, 
however, was negatively correlated with potency as a reinforcer (Ritz & Kuhar, 
1989). Further, the potency of re-uptake blockers for DAT relative to SERT was 
positively correlated with reinforcing potency (D Roberts et al., 1999). Similarly, the 
reinforcing potency of a group of compounds with similar DA-releasing abilities was 
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dependent on their ability to release 5HT. Reinforcing potency was positively 
correlated with the relative release of DA: 5HT (Wee et al., 2005). 
Pharmacological manipulations of 5HT altered the reinforcing potency of a 
range of abused drugs. Reuptake inhibitors, the releasing stimulant d-fenfluramine (d-
fen), and the 5-HT precursor, L-tryptophan, decreased AMPH (Porrino et al., 1989; F. 
L. Smith, Yu, Smith, Leccese, & Lyness, 1986), METH (Munzar, Baumann, Shoaib, 
& Goldberg, 1999), COC (Carroll, Lac, Asencio, & Kragh, 1990a, 1990b; Czoty et 
al., 2002; Howell & Byrd, 1995; A. McGregor, Lacosta, & Roberts, 1993; Negus, 
Mello, Blough, Baumann, & Rothman, 2007; Porrino et al., 1989), heroin (Higgins, 
Wang, Corrigall, & Sellers, 1994; Y. Wang, Joharchi, Fletcher, Sellers, & Higgins, 
1995) and morphine (Raz & Berger, 2010) self-administration.  
Other studies have shown that decreased 5HTergic transmission facilitated 
self-administration. pCPA pre-treatment, which induced about an 80% reduction in 
whole-brain 5HT levels, increased ethanol (EtOH) self-administration (Lyness & 
Smith, 1992). Dorsal and median raphe, medial forebrain bundle (MFB) or 
intracerebroventricular (icv) lesions produced by the selective 5HT neurotoxin, 5, 7- 
dihydroxytryptamine (5,7- DHT), resulted in significantly higher levels of AMPH 
self-administration (Fletcher, Korth, & Chambers, 1999; Leccese & Lyness, 1984; 
Lyness, Friedle, & Moore, 1980). Bilateral NAc 5, 7 -DHT lesions increased 
morphine self-administration (J. E. Smith, Shultz, Co, Goeders, & Dworkin, 1987), 
but similar lesions did not alter AMPH self-administration (Lyness et al., 1980). icv, 
intra-amygdala, and MFB 5, 7-DHT lesions increased the break-points on a 
progressive ratio schedule (Loh & Roberts, 1990; DCS Roberts, Loh, Baker, & 
Vickers, 1994) 
 
Acquisition of Self-administration 
Most self-administration studies have examined effects of manipulations 
following acquisition of self-administration. Some, however, have documented 
acquisition profiles in order to determine factors that might impact susceptibility to 
drug dependence. Variability in basal extracellular DA was related to susceptibility to 
self-administer drugs; basal levels of striatal DA were inversely related to the number 
of responses produced during acquisition of COC (Glick, Raucci, Wang, Keller Jr, & 
Carlson, 1994).  
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One means of measuring factors that might influence susceptibility to the 
positive reinforcing effects of drugs is to examine acquisition profiles. The latency to 
acquire COC and AMPH self-administration was inversely related to the dose of drug; 
higher doses led to more rapid acquisition (Carroll & Lac, 1997; Schenk et al., 1993; 
Van Ree, Slangen, & de Wied, 1978). Therefore, changes in susceptibility can be 
examined by measuring shifts in the acquisition curves. More rapid acquisition would 
suggest a more sensitive response whereas delayed acquisition would suggest a less 
sensitive response.   
One factor that has been shown to alter the latency to acquisition of self-
administration is prior drug exposure. The acquisition of AMPH self-administration 
was facilitated following pre-treatment with AMPH (Piazza, Deminière, Le Moal, & 
Simon, 1989), and pre-treatment with COC produced a leftward shift in the 
acquisition curve for COC self-administration (Horger, Shelton, & Schenk, 1990). 
The acquisition of self-administration was also altered by pre-treatment with some 
drugs that were different from the self-administration drug. For example, the repeated 
administration of MDMA, nicotine, or AMPH enhanced the acquisition of self-
administration of low-doses of COC self-administration (Fletcher, Robinson, & 
Slippoy, 2001; Horger, Giles, & Schenk, 1992). The pharmacological basis for these 
data is thought to be due to the drug pre-treatment inducing sensitisation of the 
mesolimbic DAergic system (Kalivas, Sorg, & Hooks, 1993; Kalivas & Stewart, 
1991; Sorg & Kalivas, 1991) which facilitates the reinforcing effects of drug.  
There are other predisposing factors in drug self-administration that have also 
been attributed to enhanced DA responses. Rats that display a heightened behavioural 
response to a novel (but not familiar) environment (HR rats) were more likely to self-
administer COC and AMPH (Dellu, Piazza, Mayo, Le Moal, & Simon, 1996; Hooks, 
Jones, Smith, Neill, & Justice, 1991; Mandt, Schenk, Zahniser, & Allen, 2008; Piazza 
et al., 1990; Piazza et al., 1989; Rougé‐Pont, Deroche, Moal, & Piazza, 1998). HRs 
showed an upward shift of the COC dose-effect curve and COC self-administration 
was maintained by lower doses than Low Responders (LR). This might reflect the 
increased DAergic response to drugs by HR rats. Extracellular DA was higher in HRs 
after COC administered either peripherally (Hooks et al., 1991) or directly into the 
NAc (Hooks et al., 1994).  
Food restriction also facilitated the acquisition of self-administration of 
different classes of drug, using different routes of administration and in a range of 
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species (Carroll, 1985; Carroll, France, & Meisch, 1979; Carroll & Lac, 1993; Oei, 
1983; Papasava, Singer, & Papasava, 1986). The extent of the food restriction, as 
measured by percentage of body weight lost, was correlated with the rate of 
acquisition of COC self-administration (De Vry, Donselaar, & Van Ree, 1989). Food 
deprivation also enhances the DAergic response to drugs of abuse. Sensitisation of the 
increase in extracellular DA induced by repeated treatment with a range of drugs was 
augmented following food-deprivation (Cadoni, Solinas, Valentini, & Di Chiara, 
2003).  
 
MDMA Self-administration 
The data show that DA neurotransmission underlies the reinforcing effects of 
drugs of abuse; manipulations that increase DA increase self-administration. But the 
preferential neurochemical effect of MDMA is to increase 5HT neurotransmission, 
which is inhibitory to self-administration. Based on its neurochemical effects, 
therefore, MDMA would not be expected to be self-administered. MDMA, however, 
is abused by humans, and is self-administered by monkeys (Beardsley, Balster, & 
Harris, 1986; Fantegrossi, Ullrich, Rice, Woods, & Winger, 2002), baboons (Lamb & 
Griffiths, 1987), rats (Ratzenboeck, Saria, Kriechbaum, & Zernig, 2001), and mice 
(Trigo, Panayi, Soria, Maldonado, & Robledo, 2006). 
Like all other drugs of abuse, racemic, (+)- and (-)- MDMA produce dose-
dependent responding in the shape of an inverted U; high and low doses are self-
administered at low levels, and intermediate doses are self-administered at higher 
levels (Beardsley et al., 1986; Fantegrossi et al., 2002; Fantegrossi et al., 2004; Lamb 
& Griffiths, 1987; Schenk, Gittings, Johnstone, & Daniela, 2003).  
Early MDMA self-administration experiments employed a substitution 
method, whereby (±)-MDMA was introduced to COC-trained animals (Beardsley et 
al., 1986; Lamb & Griffiths, 1987; Schenk et al., 2003). In the first experiment, 3 of 
the 4 monkeys tested self-administered MDMA, indicating that MDMA produced 
reinforcing effects. Further, at one dose, 100ug/kg/ infusion, 2 of the monkeys 
responded more than when COC was self-administered (Beardsley et al., 1986).  
Subsequent studies, however, reported low levels of responding maintained by 
MDMA and high levels of variability between subjects. COC-trained baboons 
responded for about 5-6 infusions of MDMA (1.0 mg/kg/infusion) in a 24hr session 
(Lamb & Griffiths, 1987). Initial studies in rodents revealed extremely low numbers 
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of responses, and responding was not dose-dependent. Rats that were initially trained 
to perform an operant to receive food pellets self-administered about 3-4 infusions per 
session, regardless of dose (De La Garza II, Fabrizio, & Gupta, 2007; Ratzenboeck et 
al., 2001). In one study, only 1 of 5 rats tested responded reliably (De La Garza II et 
al., 2007). Because responding maintained by MDMA was low, researchers suggested 
that MDMA had relatively weak reinforcing effects (Beardsley et al., 1986; Lamb & 
Griffiths, 1987). More recent MDMA self-administration studies, however, have 
reported higher levels of responding (Bradbury et al., 2013; Do & Schenk, 2011; 
Reveron et al., 2010; Schenk, Colussi-Mas, Do, & Bird, 2012; Schenk et al., 2003; 
Schenk et al., 2007). The failure of earlier studies to find reliable MDMA self-
administration might be due to methodological disparities; in particular MDMA dose, 
and drug infusion length (De La Garza II et al., 2007), or the number of test sessions. 
High rates of MDMA self-administration was produced only after an average of 15 
daily test sessions (Schenk et al., 2012).  
There are many aspects of MDMA self-administration that differentiate it 
from the self-administration of other drugs. First, the acquisition of MDMA self-
administration is not dose-dependent. The proportion of rats that acquired MDMA 
self-administration and the latency to acquisition was comparable when 1.0 and 0.25 
mg/kg MDMA were tested (Schenk et al., 2007). The latency to acquire AMPH and 
COC self-administration, however, was inversely related to the dose of drug (Carroll 
& Lac, 1997; Schenk et al., 1993; Van Ree et al., 1978).  
Second, the latency to acquisition of MDMA self-administration is much 
longer than the latency to acquisition for COC and AMPH. Whereas self-
administration of moderate to high doses of COC and AMPH is acquired within a 
small number of limited-access daily sessions (e.g. Carroll & Lac, 1997), 15 test 
sessions are typically required for MDMA self-administration (Schenk et al., 2012). 
This is reflected in the low level of responding for MDMA found during initial 
sessions (Reveron et al., 2010; Schenk et al., 2003; Schenk et al., 2007).  
Third, the most striking difference between the acquisition of MDMA self-
administration and that of other drugs is the number of subjects that acquire self-
administration. Our laboratory consistently finds that only about 50% of test subjects 
acquire MDMA self-administration (Schenk et al., 2012). The self-administration of 
moderate and high doses of drugs such as COC and AMPH, however, is acquired by 
the vast majority of subjects (e.g. Carroll & Lac, 1997). 
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Once MDMA self-administration has been acquired, it becomes comparable to 
that of AMPH or COC in that responding became dose-dependent (Schenk et al., 
2003; Schenk et al., 2007). Coincident with the change in the behavioural profile is a 
change in the neurochemical effects of MDMA. The DAergic response to MDMA 
became augmented (Colussi-Mas et al., 2010) and the 5HT response decreased 
(Reveron et al., 2010), and tissue levels of 5HT, but not DA, were decreased (Do & 
Schenk, 2011; Schenk, Gittings, & Colussi‐Mas, 2011) following MDMA self-
administration. Further, similar to what is found with other psychostimulants, 
DAergic mechanisms were associated with MDMA-seeking following extensive self-
administration. Drug seeking following the self-administration of MDMA was 
reinstated by the D2 agonist, quinpirole, the DA releaser, AMPH, and the DA 
reuptake inhibitor, GBR 12909 (Schenk et al., 2011); and MDMA-produced drug-
seeking was attenuated by the D1 antagonist, SCH 23390, and the D2 antagonist, 
eticlopride (Schenk et al., 2011).  
It appears then, that MDMA self-administration progresses with changes of 
the neurochemical response. Initially, the 5HT response is marked and responding for 
MDMA is low. Following repeated testing, the 5HT response is decreased and the DA 
response is increased, and responding is comparable to that maintained by AMPH or 
COC. 
 
Current Thesis 
The current thesis aims to test the ideas that (1) susceptibility to acquire 
MDMA self-administration is related to the MDMA-produced 5HT response, (2) 
MDMA self-administration progresses as the MDMA-produced 5HT response 
decreases and the MDMA-produced DA response increases, and (3) that responding 
maintained by MDMA is not dependent on 5HT neurotransmission. Based on 
previous literature, it was hypothesised that the acquisition of MDMA self-
administration is initially limited by the MDMA-produced 5HT response, but that this 
response decreases with repeated exposure to MDMA. The MDMA-produced DA 
response was hypothesised to concurrently increase, and to underlie the maintenance 
of MDMA self-administration. 
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General Methods 
 
The methodology contained in this section was used for each and every experiment 
undertaken for this thesis. The methods sections contained in chapters describe any 
further methodology required for individual experiments. 
 
Animals 
Male Sprague-Dawley rats weighing between 290 and 330g at the start of the 
experiment were used. The rats were bred in the vivarium at Victoria University of 
Wellington and housed in groups of 4 until they weighed 280g. Thereafter, they were 
housed individually in hanging polycarbonate cages for 4 days prior to surgery. The 
animal colony was humidity- (55%) and temperature- (21° C) controlled, and was on 
a 12/12 hour light cycle, with lights on at 0700 hr. Food and water were available ad 
libitum except during testing. All procedures were approved by the Animal Ethics 
Committee at Victoria University of Wellington. 
 
MDMA Self-Administration Testing 
Surgery 
All rats were surgically implanted with an intrajugular catheter. Deep 
anaesthesia was produced by an injection of ketamine (90.0 mg/kg, ip, 
PhoenixPharm) and xylazine (9.0 mg/kg, ip, Provet), and this was followed by an 
injection of the anti-inflammatory anaesthetic, Carprofen® (5.0 mg/kg, sc, Pfizer 
Animal Health). Briefly, the external jugular vein was isolated from surrounding 
tissue and tied off. An incision was made in the vein and a silastic catheter (Dow 
Corning, Midland, MI, USA) was inserted and fixed. The distal end of the catheter 
was then threaded subcutaneously to the exposed skull.  
A compound sodium lactate solution (Hartmann’s solution, 2 x 6ml, sc) was 
administered to restore electrolyte balance. Carprofen® (5.0 mg/kg, sc) was 
administered on each of the two days following surgery. Catheters were infused with 
0.2 mL of a sterile 0.9% heparinised saline solution, containing penicillin G 
potassium (250,000 IU/mL) each day for 3 days post-surgery. 
 
Apparatus 
26 
 
Self-administration was conducted in operant chambers (Med Associates, 
ENV-001, St Albans, VT, USA) equipped with 2 levers. Depression of the right, 
‘active’ lever resulted in a 12 second intravenous infusion of 0.1 mL ±MDMA (1.0 
mg/kg/infusion, Environmental Science and Research Ltd, Porirua, New Zealand; 
Experiments 1 and 2) and the illumination of a stimulus light located directly above 
the active lever. Depression of the left, ‘inactive’ lever was recorded but had no 
programmed response. The 1.0 mg/kg dose of MDMA was chosen because it has 
been demonstrated to produce reliable acquisition of self-administration (Schenk et 
al., 2003; 2007; 2012).  
 
Procedure 
Each day, prior to self-administration testing, catheters were flushed with 0.2 
mL of the heparinised penicillin solution. Daily test sessions were 2 hours in duration, 
6 days a week. Each session commenced with an experimenter-administered infusion 
of 0.1 mL drug to clear the catheter of the penicillin solution. Thereafter, drug 
infusions of MDMA (1.0 mg/kg/ infusion) were delivered according to a fixed ratio 1 
schedule of reinforcement. Testing continued for 25 daily sessions, or until the session 
during which the total cumulative amount of self-administered MDMA reached 90±5 
infusions, whichever came first. Rats that met this criterion within the 25 day cut-off 
were considered to have acquired (ACQ) and those that failed to meet the criterion 
within this test period were considered to have not acquired (NO-ACQ) self-
administration. The latency to acquisition was defined as the number of test sessions 
required to meet this acquisition criterion.  
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Chapter 1 
This chapter has been adapted from Bradbury et al. (2013) 
Introduction 
The experiments of Chapter 1 sought to elucidate whether the variability in 
acquisition of MDMA self-administration could be explained by the MDMA-induced 
increase of synaptic 5HT or DA. Variability in COC and AMPH self-administration 
has previously been attributed to differences in drug-induced increases of synaptic 
DA (Nelson, Larson, & Zahniser, 2009; Piazza et al., 1991). MDMA differs from 
COC and AMPH, however, in that it preferentially increases synaptic 5HT. This 
would be expected to limit the acquisition of self-administration because of inhibitory 
effects on DA. If so, it was expected that the latency to acquisition of MDMA self-
administration would be negatively related to the MDMA- produced 5HT response 
and positively related to the DA response. In order to investigate these possibilities 
extracellular levels of 5HT and DA in response to an acute injection of MDMA were 
measured prior to the commencement of MDMA self-administration.  
Microdialysis probes were aimed at the shell of the NAc. Previous research 
has documented that drugs of abuse, including MDMA, induce a preferential increase 
in shell DA relative to the core (Cadoni et al., 2005), that has been related to the 
drugs’ reinforcing properties (Di Chiara, 1999). 
 
Method 
Experimental Overview 
 
 
 
 
 
 
 
Surgery 
Concurrent with the implantation of the jugular catheter (as described in the 
General Methods), a guide cannula (MAB 4.15.IC, microbiotech, Sweden) was 
Day 0 
Surgery to insert 
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Day 7 
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Day 9/ 10 
Self- 
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Day y 
Histology 
Day x 
Self-
administration 
completed. 
Brain 
removed 
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stereotaxically implanted 1mm above the right NAc (antero-posterior +1.0mm from 
bregma, lateral -0.85mm from midline, ventral -5.5mm from dura; Paxinos & Watson, 
2006). The cannula was fixed to the skull alongside the distal end of the catheter using 
dental screws and dental acrylic.  
 
Microdialysis 
Procedure 
Six days following surgery, the rats were transported to the testing room and 
held in a transparent plastic cage. A microdialysis probe (MAB 4.15.2.Cu, 
Microbiotech, Sweden) was inserted into the guide cannula and protruded 3mm past 
the guide (membrane length: 2mm). Artificial cerebrospinal fluid (149 mmol/L NACl; 
2.8 mmol/L KCl; 1.2 mmol/LMgCl2; 1.2 mmol/LCaCl2; 0.45 mmol/LNaH2PO4; 2.33 
mmol/LNa2HPO4, pH 7.4) was perfused through the probe overnight at a flow rate of 
1.0 µL/min. Probe recovery rates were calculated individually for each rat following 
perfusion with known concentrations of DA and 5HT and averaged 12.3 ± 1.9% for 
DA and 18.4 ± 2.2% for 5HT.  
The following day, the rat was moved into a clear, plexiglass chamber of 
dimensions 42 × 42 × 30 cm, which served as the testing chamber and 3 baseline 
samples were collected at 30 min intervals in a tube containing 3.75 µL 0.01 N PCA. 
Each rat then received an injection of 1.0 mg/kg MDMA (iv) followed, 2 hours later, 
by an injection of 3.0 mg/kg MDMA (iv). Dialysis samples were collected at 30 
minute intervals for 2 hours after each injection. The microdialysis probe was then 
removed from the guide, the dummy cannula was re-inserted, and the rats were 
returned to their home cage. Self-administration testing began 2 to 3 days later. 
 
Dialysate Analysis 
The concentration of DA and 5HT in dialysates was determined using high 
performance liquid chromatography (HPLC; 1100 series, Agilent, Santa Clara, CA, 
USA) equipped with a coulometric detector (Coulochem III, ESA Inc., Chelmsford, 
MA, USA). Samples were split for the purpose of analysis. For DA, 10 L of 
dialysate was injected onto a column (C18 reversed phase; Agilent Eclipse XDB-C18, 
4.6  150 mm, 5 m particle size) and the mobile phase consisted of 75 mmol/L 
NaH2PO4, 1.7 mmol/L octanesulfonic acid, 0.25 mmol/L EDTA, 100 L/l 
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triethylamine, 10% (v/v) acetonitrile, pH 3, delivered at a constant flow rate of 
1.0 ml/min. For 5HT, 20 L of dialysate was injected into a C18 reversed phase 
column (Luna C18(2), 2.0  100 mm, 3 m particle size, Phenomenex). The mobile 
phase consisted of 90 mmol/L NaH2PO4, 1.7 mmol/L octanesulfonic acid, 50 mol/L 
EDTA, 50 mmol/L citric acid, 10% (v/v) acetonitrile, pH 3, delivered at a constant 
flow rate of 0.2 mL/min. Chromatograms were acquired with ChemStation software 
and peak heights of samples were compared to peak heights of standards with known 
concentrations of DA or 5HT. Concentrations are expressed as nmol/L, corrected for 
probe recovery. The lower limit of detection for DA was 3 fmol, and for 5HT 0.88 
fmol. 
 
Histology 
Following the completion of self-administration testing, rats were sacrificed 
by CO2 asphyxiation and the brains were removed and stored at -80°C. Brains were 
sliced on a cryostat in 60 or 80µm sections and sections were stained with Neutral 
Red. Sections were examined by an experimenter blind to the results and data from 
rats with incorrect placements were not included in any analyses. A complete set of 
samples for 5HT was collected from 14 rats (n=7 acquired; n=7 non-acquired) and for 
DA from 12 rats (n=7 acquired; n=5 non-acquired. Nb, samples from 2 non-acquired 
rats were lost due to hplc problems). 
 
Data Analysis 
Active and inactive lever responding for the ACQ and NO-ACQ groups were 
compared for the first 3 and last 3 days of responding maintained by MDMA using a 
three-way analysis of variance (ANOVA; Group X Lever X Training). Post-hoc tests 
were conducted using the Bonferroni correction. MDMA-induced changes in DA and 
5HT were expressed as a percentage of the baseline value, calculated as the average 
of the initial three baseline samples collected in the testing chamber. Changes in 
MDMA-induced DA and 5HT overflow for the ACQ or NO-ACQ group were 
evaluated using a three-way ANOVA (Group X Time X Dose) followed by post hoc 
tests using the Bonferroni correction . Correlations were conducted between the 
MDMA-induced increases of 5HT and DA, expressed as either the average 
concentration across the 4 samples or as the peak concentration, and the acquisition 
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data, expressed as either the number of sessions required to reach the acquisition 
criterion or the average MDMA intake over the last 3 days of self-administration 
testing. 
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Results 
 
MDMA self-administration 
Figure 1.1 depicts the location of the microdialysis probes. The acquisition 
criterion was met by 7 of the 14 rats.  The 90 infusions of 1.0 mg/kg/infusion MDMA 
were self-administered in an average of 15 test sessions (range = 7-22 days), 
consistent with previous findings from our laboratory (Schenk et al., 2012).  
 
 
 
 
 
Figure 1.2 shows the average number of lever responses during the first 3 and 
the last 3 days of MDMA self-administration for the ACQ and the NO-ACQ groups. 
The ACQ group reached the acquisition criterion in an average of 14.8 (±1.8) test 
sessions. A significant Group X Lever X Training interaction was found (F(1,12)= 6.05, 
p < 0.05). Significant Lever X Training (F(1,12)= 10.69, p < 0.05), and Group X Lever 
(F(1,12)= 10.79, p < 0.05) interactions were found. During initial test sessions 
responding on the active lever was low for both groups, but with repeated daily 
Figure 1.1 Location of microdialysis probes for the Acquired (left panel; n= 7) and Not 
Acquired (right panel; n= 7) groups, adapted from Paxinos& Watson (2005) 
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training, responding on the active lever increased significantly in the ACQ group ( p < 
0.05). On the last 3 days of self-administration, the number of active lever responses 
produced by the ACQ rats was significantly higher than both the number of inactive 
lever responses ( p < 0.05) and the number of active lever responses in the NO-ACQ 
group (p <0.05). 
 
Relationship between the neurochemical response to the initial exposure to MDMA 
and acquisition of MDMA self-administration  
The basal concentrations of 5HT or DA were not significantly different 
between rats from the ACQ (5HT; 1.1  0.3 nmol/L; DA; 11.7  4.5 nmol/L) and NO-
ACQ (5HT; 0.9  0.2nmol; DA; 9.1  2.3 nmol/L) groups (5HT; F(1,10)=0.020, n.s; 
DA; F(1,12)=0.388, n.s.). Figure 1.3 graphs the MDMA-induced increases of 5HT 
(upper panel) and DA (lower panel) relative to baseline. For 5HT, a 3-way ANOVA 
(Dose X Sample X Group) revealed a significant main effect of Dose (F(1,12)= 14.88, 
p < 0.05) but not of Group (F(1,12)= 4.32, n.s.).There was a significant Group X Dose 
interaction (F(1,12)= 5.13, p < 0.05) and post-hoc tests confirmed that the increase 
following 3.0 mg/kg MDMA was higher for the NO-ACQ group (p<0.05). For DA, a 
Figure 1.2 The average number of responses on the active and inactive levers for the first 3, 
and last 3, days of self-administration testing for both the ACQ (n= 10) and NO-ACQ (n= 8)  
groups. * p < 0.05 compared to inactive lever responses for the last 3 days, active lever 
responses for the first 3 days by the ACQ group, and active lever pressing for the last 3 days 
by the NO-ACQ group. 
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3-way ANOVA (Dose X Sample X Group) revealed only a significant main effect of 
Dose (F(1,10)=5.17, p < 0.05). 
Figure 1.3 shows the MDMA-produced percent increase in 5HT and DA as a function 
of baseline neurotransmitter levels. Percent increases are shown for the ACQ group 
and NO-ACQ group for 4 samples collected following 1.0 or 3.0 mg/kg MDMA. * p< 
0.05 compared to the MDMA-induced increase in 5HT of the ACQ group  
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The variability in latency to reach the acquisition criterion, however, was not 
related to 3.0 mg/kg MDMA-induced increases of 5HT or DA. The 5HT response, 
measured as the average concentration of the 4 samples (M= 13.23, SD= 12.68), or 
the peak concentration of 5HT (M= 6.26, SD= 5.66) was not correlated with days to 
acquisition (M= 14.75, SD= 5.12), r= 0.336, p= n.s and r= 0.355, p= n.s, respectively. 
Similarly, no correlation was found between average extracellular levels of DA 
averaged out over the 4 samples (M= 40.81, SD= 29.67) or the peak increase of DA 
(M=14.40, SD= 11.02) and days to acquire self-administration, r= 0.472, p= n.s and 
r=0.290, p= n.s, respectively.  
In addition, there was no significant relationship between the extracellular 
levels of 5HT- whether the average of the 4 samples or the peak concentration was 
used- and the average number of infusions over the last 3 self-administration sessions 
(M=10. 5, SD= 4.07), r= -0.398, p= n.s and r= -0.432, p= n.s, respectively. Likewise, 
neither average extracellular DA nor peak DA significantly correlated with the 
average number of infusions over the last 3 self-administration sessions, r= 0.01, n.s 
and r=-0.16, p=n.s, respectively. 
Figure 1.4 plots the number of infusions of MDMA obtained over the last 3 
self-administration test sessions as a function of the MDMA-produced increases in 
5HT (top) and DA (bottom) for individual rats. Although all analyses revealed non-
significant results, a trend exists in that greater MDMA-induced increase in 5HT 
corresponded with fewer infusions of self-administered MDMA.  
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Figure 1.4 plots the number of infusions of MDMA obtained over the last 3 self-administration 
test sessions as a function of the MDMA-produced increases in 5HT (top) and DA (bottom) for 
individual rats. 5HT and DA levels are represented by the area under the curve produced by 
plotting the concentration of neurotransmitter across time. 
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Discussion 
Acute exposure to MDMA increased both DA and 5HT overflow and as has 
been previously documented (Baumann, Clark, Franken, Rutter, & Rothman, 2008; 
Baumann, Clark, & Rothman, 2008; Kurling, Kankaanpää, & Seppälä, 2008; O'Shea 
et al., 2005; Reveron et al., 2010),  the 5HT response was more pronounced. The 
DAergic response to MDMA was dose-dependent and the magnitude of the increase 
was similar to that previously reported following administration of the same doses, 
administered in the same manner (Baumann, Clark, & Rothman, 2008).  There was, 
however, no difference in the magnitude of the DA response for the rats that acquired 
or failed to acquire MDMA self-administration. MDMA also increased 5HT overflow 
in a dose-dependent manner, and the magnitude of the increase was also comparable 
to what has previously been reported following the same injection protocol (700% and 
1445% for 1.0 mg/kg and 3.0 mg/kg, respectively; Baumann, Clark, & Rothman, 
2008). The MDMA-induced increase in 5HT following the 3.0 mg/kg injection was, 
however, significantly higher for the group that subsequently failed to meet the 
criterion for MDMA self-administration suggesting that 5HT impacts MDMA self-
administration.  
Although 1.0 mg/kg was the self-administered dose, the effect of a single 
infusion of this dose of MDMA on 5HT was not different for the acquired and not 
acquired groups. Only the effect of the higher dose of 3.0 mg/kg produced an effect 
that was different for the two groups. This might suggest that the effects are not 
relevant to the MDMA self-administration data. During self-administration testing, 
however, rats are exposed to multiple infusions of the 1.0 mg/kg dose of MDMA. 
Further, as self-administration progresses, the average intake increases and exceeds 
3.0 mg/kg per session.  One cannot, therefore, directly compare the effect of a single 
experimenter-administered infusion to effects produced by multiple self-administered 
infusions.  
The data suggest that MDMA self-administration is, at least initially, inhibited 
by MDMA-induced increases of 5HT. There was no relationship however, between 
latency to acquisition and MDMA-induced increases of 5HT. Thus individual 
differences in the 5HTergic response to MDMA may predict whether or not the 
subject will acquire MDMA self-administration, but not the latency to acquire self-
administration. 
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A wealth of data has implicated the mesolimbic DAergic system in the 
reinforcing effects of psychostimulants (for a review, see Wise, 1998), including 
MDMA (Brennan et al., 2009; Daniela et al., 2004), and propensity to acquire 
psychostimulant self-administration was correlated with greater DA turnover and 
increased drug-induced extracellular DA in the NAc (Hooks, Colvin, Juncos, & 
Justice Jr, 1992; Marinelli & White, 2000; Piazza et al., 1991). In addition, the latency 
to acquire self-administration was negatively correlated with drug-induced DA 
(Carroll & Lac, 1997; Schenk et al., 1993; Van Ree et al., 1978). Accordingly, the 
MDMA-produced DA response of the ACQ rats may have been expected to be higher 
because of either a greater direct effect of MDMA on DA or because of the indirect, 
and reduced inhibitory, effect of 5HT on DA. This response was, however, 
comparable regardless of whether the rats acquired or failed to acquire MDMA self-
administration. Further, the magnitude of the MDMA-induced DA release was not 
indicative of the latency to acquire MDMA self-administration.  
The MDMA-produced increase in DA was modest compared to effects 
produced by other self-administered drugs (Ranaldi, Pocock, Zereik, & Wise, 1999; 
Suto, Ecke, You, & Wise, 2010; Weiss et al., 1992). It is therefore possible that the 
initial MDMA-produced increase in DA was insufficient to reinforce operant 
responding. Indeed, this might explain why none of the rats reliably self-administered 
MDMA during the first several sessions. It has been suggested that repeated exposure 
to small amounts of MDMA during the first few sessions is sufficient to produce 
deficits in 5HT neurotransmission for some of the rats, leading to a disinhibition of 
mesolimbic DA and the development of reliable self-administration; increased self-
administration would then produce additional 5HT deficits and a more substantial 
disinhibition of DA (Schenk, 2011).  Following experimenter-administered MDMA 
that induced a decrease in 5HT levels equivocal results on DA overflow have been 
reported with increased (Kalivas et al., 1998), or no change in DA levels (Baumann, 
Clark, Franken, et al., 2008; Shankaran & Gudelsky, 1999). In the limited number of 
studies that have investigated the effects of self-administered MDMA, low levels of 
self-administration failed to alter MDMA-induced DA overflow (Reveron et al., 
2010) but more extensive self-administration increased MDMA-induced DA overflow 
to a greater extent for the ACQ group (Colussi-Mas et al., 2010). 
The results of Chapter 1 demonstrate that the variability to acquire MDMA 
self-administration is not likely related to small, initial increases in DA levels, but 
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might be due to differences in the ability of MDMA exposure to enhance 5HT 
neurotransmission. In particular, the data suggest that greater MDMA-induced 
increases of 5HT were inhibitory to acquisition of self-administration. If so, then a 
reduction of the MDMA-produced 5HT response should facilitate the acquisition of 
MDMA self-administration. This idea can be tested experimentally by manipulating 
MDMA-induced increases of 5HT. One way to decrease 5HT is via neurotoxic 5, 7 – 
DHT lesions. Previous research has shown that these lesions increased responding 
during acquisition of AMPH self-administration (Leccese & Lyness, 1984; Lyness et 
al., 1980). If 5HT also inhibits acquisition of MDMA self-administration, then it was 
expected that the lesion would facilitate acquisition, as measured by a decrease in 
latency. 
 
 
 
39 
 
Chapter 2 
 
This chapter has been adapted from Bradbury et al. (2013). 
 
Introduction 
The results of Chapter 1 showed that synaptic 5HT overflow following initial 
MDMA was increased to a lesser extent for the rats that subsequently acquired 
MDMA self-administration. If the variability in susceptibility to self-administer 
MDMA is negatively impacted by MDMA-induced increases of 5HT, then the 
widespread depletion of brain 5HT should enhance susceptibility to self-
administration. This idea was tested in the experiment of Chapter 2.  
The neurotoxin, 5, 7-DHT, produces the widespread depletion of 5HT and NE. 
The meta-substituted dihydroxytryptamine is taken up into 5HTergic and NEergic 
neurons via the uptake transporter. Once transported into the cytosol, 5,7- DHT is 
metabolised by MAO and aldehyde dehydrogenase to form a dihydroxyindoleactic 
acid. This acid, along with deaminated 5, 7- DHT interacts with cytochrome-C 
oxidase of the mitochondria and together they are subjected to enhanced oxidation. 
This oxidation appears to be the greatest factor in the production of the neurotoxic 
effects, as the resulting intermediates attack nucleophiles in peptides and proteins to 
inactivate the –SH and –NH2- functional groups. 
Because 5, 7-DHT is transported into neurons via the uptake transporters it 
can be used as a selective 5HT neurotoxin by co-administering a NE transporter 
(NET) inhibitor to prevent uptake into NE neurons. The selective depletion of 5HT 
via icv or intra-medial forebrain bundle administration of 5,7 – DHT increased initial 
responding for AMPH (Leccese & Lyness, 1984; Lyness et al., 1980). The experiment 
of chapter 2 used 5,7- DHT to produce widespread depletion of brain 5HT prior to the 
commencement of self-administration testing. It was hypothesised that depletion of 
brain 5HT would increase the proportion of subjects that self-administer MDMA, and 
decrease the latency to acquisition. 
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Method 
 
Experimental Overview 
 
 
 
 
 
 
Self-administration 
5, 7 - DHT was infused following implantation of the i.v catheter. In order to 
prevent uptake into NEergic neurons, the uptake inhibitor, desipramine (25mg/kg, ip, 
Sigma Aldrich, Australia), was administered at least 30 minutes prior to 
administration of 5,7-DHT. In preliminary tests, xylazine produced adverse effects in 
rats subjected to the lesion, and so, instead, sodium pentobarbital (20.0mg/kg, ip, 
Provet) was used as the aneasthetic. Following the insertion of a jugular catheter (see 
General Methods), a 28 gauge cannula (Plastics One, C313I-SPC; USA) was 
stereotaxically inserted into the left ventricle (antero-posterior -1.5mm from bregma, 
lateral -1.7mm from midline, ventral -3.5mm from dura; Paxinos & Watson, 2006) 
and 10µL 5,7-DHT (150µg freebase; Tran-Nguyen, Bellew, Grote, & Neisewander, 
2001) or the 1% ascorbic acid vehicle was infused  over a 10 min period ( 1 µL/min). 
The cannula remained in situ for 2 minutes post-injection to allow diffusion of the 
neurotoxin. Self-administration testing began 10 days later. 
 
Neurochemical Consequences of the Lesion 
Separate groups of rats (n =5 per group) were treated with 5, 7- DHT or 
vehicle, as above, and sacrificed 10 days later to measure tissue levels of 5HT and DA 
and their metabolites. Following CO2 asphyxiation, rats were sacrificed by 
decapitation, the FC and striatum were extracted and samples were stored at -80º C 
until assay. The FC was chosen because it is richly innervated with 5HTergic neurons, 
and the striatum because it is richly innervated with DAergic neurons. The samples 
were combined with 10 µL 0.1 N PCA per mg of tissue. Samples were homogenised 
Day 0 Day 7 Day y 
Catheter surgery 
and 5,7-DHT 
infused 
Self-administration 
testing commences 
Self-administration 
testing completed. 
Brains Removed. 
Histology 
Day x 
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and then centrifuged at 13,000 rpm for 30 minutes at 4º C. The supernatant was then 
filtered into vials and injected onto the column. The column and mobile phase used 
was identical to that used for DA analysis in the microdialysis experiment. 
Chromatograms were acquired with ChemStation software and peak heights of 
samples were compared to peak heights of standards with known concentrations of 
5HT, 5HIAA, DA and the DA metabolite, homovanillic acid (HVA). Regression 
analysis of the calibration curves was then used to calculate the concentration of the 
neurochemicals.  
 
Self-administration 
MDMA self-administration was carried out as reported in the General 
Methods: testing continued for 25 daily sessions, or until the session during which the 
total cumulative amount of self-administered MDMA reached 90±5 infusions, 
whichever came first. Additionally, the effect of the 5, 7-DHT lesion on the 
acquisition curve for low-dose COC self-administration (0.25 mg/kg/infusion) was 
measured for comparison. The acquisition criterion used was the same, with 90±5 
infusions required within 25 test sessions. The protocol used for COC self-
administration testing was identical to that of MDMA. 
 
Histology 
Following the completion of self-administration testing, rats were sacrificed 
by CO2 asphyxiation and the brains were removed and stored at -80°C. Brains were 
sliced on a cryostat in 60 or 80µm sections and sections were stained with Neutral 
Red. Sections were examined by an experimenter blind to the results and data from 
rats with incorrect placements were not included in any analyses. The self-
administration data from 19 rats of the MDMA groups (lesion=8; control=11) and 12 
rats of the COC groups (lesion=5; control=7) were used. 
 
Data Analysis 
The number of test sessions required to self-administer 90 infusions of 
MDMA and COC was compared for vehicle and lesion groups using the Kaplan-
Meier estimator for survival analysis that compared the mean time to event (latency to 
acquisition) between groups. The log-rank test was used to compare the survival 
curves of the lesion and control groups. The level of significance was set at p < 0.05. 
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Results 
Table 2.1 shows tissue levels of 5HT, 5HIAA, DA and HVA in the FC and 
striatum following 5, 7-DHT or vehicle. One-way ANOVAs revealed that 5,7-DHT 
substantially reduced 5HT and 5HIAA in the FC (F (1, 9) = 18.92, p< 0.05; F (1, 9) = 
17.57, p<0.05) and striatum (F (1, 9) = 5.82, p < 0.05; F( 1, 9) = 14.03, p < 0.05). 
There were no differences in DA or HVA in the FC (F( 1, 9) = 0.10, p= n.s; F (1, 9) = 
.44, p= n.s) or striatum (F (1, 9) = 0.86, p =n.s; F(1, 9) = 0.02, p=n.s.).  
 
 Frontal Cortex Striatum 
5HT  Vehicle 0.45 (0.02) 0.54 (0.06) 
5, 7- DHT 0.15 (0.02)* 0.35 (0.05)* 
5HIAA  Vehicle 0.51 (0.04) 0.82 (0.08) 
5, 7- DHT 0.23 (0.05)* 0.43 (0.07)* 
DA Vehicle 0.04 (0.00) 14.37 (1.33) 
 
5, 7- DHT 0.04 (0.00) 19.76 (5.67) 
HVA Vehicle 0.03 (0.00) 1.77 (0.58) 
 
5, 7- DHT 0.03 (0.00) 1.67 (0.27) 
 
Table 2.1 5HT and 5HIAA levels (ng/mg tissue) in the FC and striatum following administration of 5, 7- DHT or 
the vehicle. Values are mean (SEM). * denotes p< 0.05 compared to vehicle. 
 
 
Figure 2.1 shows the cumulative percentage of rats that met the criterion for 
acquisition of MDMA (left) and COC (right) self-administration as a function of test 
session. Of the 11 rats in the control MDMA group, 5 (45.45%) met the acquisition 
criterion. Following the lesion, all of the rats met the acquisition criterion for MDMA 
self-administration and the curve was shifted upwards compared to the control group 
(χ2 (1) = 7.13, p < 0.05). All control and lesioned rats met the criterion for acquisition 
of COC self-administration. The curve for the lesion group was shifted leftwards 
compared to the control group (χ2 (1) = 8.49, p < 0.05).  
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Figure 2.2 shows active lever responses for a representative control (top panel) 
and lesion (bottom panel) rat during 2-hour self-administration test sessions on days 
during acquisition testing. The lesion rat met criterion on Day 4 and the control rat on 
Day 8. Total responses during each daily session are noted on the right axis. During 
initial test sessions, both rats responded on the active lever throughout the 2 hours. 
During subsequent sessions, however, the lesioned rat responded during the first third 
of the test session only, whereas the control rat continued to respond throughout the 2 
hours. 
 
Figure 2.1shows the cumulative acquisition curves for the lesion and control groups 
self-administering MDMA (top) or COC (bottom). 
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Discussion 
In order to directly test the idea that 5HT negatively impacts the acquisition of 
MDMA self-administration, the latency to acquisition of self-administration was 
Figure 2.2 shows the temporal pattern of active lever responding for a representative control (top panel 
and lesion (bottom panel) rat during the 2-hour self-administration sessions. Data from the lesioned rat 
are shown during the 4 days required to reach criterion and for the control rat during the 8 days required 
to reach criterion. Each vertical symbol represents a lever response. Total number of responses for each 
session is noted on the right side 
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measured following brain 5HT depletion produced by neurotoxic 5,7-DHT lesions. 
The lesion markedly increased the percentage of rats that acquired MDMA self-
administration and appeared to decrease the latency to acquisition defined as the 
number of test sessions required to reach the criterion for acquisition of self-
administration. When COC self-administration was measured, all rats in both the 
lesion and control groups met the criterion for acquisition of self-administration but  
the latency to acquisition of COC self-administration was reduced by the lesion. 
These findings are similar to the effect of the lesion that has been observed when the 
acquisition or maintenance of self-administration of other drugs was measured 
(Leccese & Lyness, 1984; Lyness et al., 1980; Pelloux, Dilleen, Economidou, 
Theobald, & Everitt, 2012).  
A leftward shift in the COC self-administration acquisition curve has been 
attributed to an increased potency since it is comparable to the effect of increasing 
drug dose; in both cases, the latency to acquisition of self-administration is shorter 
(Schenk, Horger, Peltier, & Shelton, 1991; Schenk et al., 1993). Unlike COC self-
administration, however, the latency to acquisition of MDMA self-administration is 
not altered by dose. In particular, the acquisition curve for self-administration of dose 
of 0.25 mg/kg/ infusions MDMA was not significantly different from the acquisition 
curve produced when 1.0 mg/kg/ infusion was self-administered (Schenk et al., 2007); 
both the percentage of subjects that met criterion and the number of days to acquire 
self-administration were comparable regardless of dose. This suggests that, for a 
substantial proportion of subjects, MDMA self-administration is limited by specific 
effects of the drug. This specific effect was overcome following the 5,7 DHT lesion 
so that the percentage of rats that met the criterion with the 25 day test period 
increased to 100%. These findings are consistent with the idea that susceptibility to 
self-administer MDMA is limited by the 5HTergic response to MDMA during initial 
exposures, as was suggested by the data obtained in Chapter 1. 
Analysis of the pattern of responding within test sessions highlighted 
differences in responding between the lesion and control groups. During initial test 
sessions, rats in both groups responded sporadically throughout the session. With 
repeated testing, responding increased for rats in both treatment groups. Responding 
by the control rat was distributed throughout the test session but responding by the 
lesioned rat became restricted to the initial portion of the session. MDMA-produced 
5HT may, therefore, limit rapid responding for the drug. Perhaps the most pronounced 
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feature of the lesion group’s time-course of responding was that no responses were 
made in the second half of the test session, which probably reflects the long half-life 
of MDMA (Schenk et al., 2003).  
The data of Chapter 2 show that the global reduction of 5HT facilitates the 
acquisition of MDMA self-administration. The results therefore provide further 
support for the idea that the acquisition of MDMA self-administration is inhibited by 
MDMA-induced increases of 5HT. For some rats, this inhibiting action of 5HT must 
be overcome and MDMA self-administration is acquired. It has been suggested that 
this occurs as repeated exposures to small amounts of MDMA produce deficits in 
5HT neurotransmission, leading to a disinhibition of DA (Schenk, 2011). If this is the 
case, MDMA-induced increases of 5HT should be reduced and MDMA-induced 
increases of DA augmented, following the acquisition of MDMA self-administration. 
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Chapter 3 
 
Introduction 
The results from Chapters 1 and 2 support the idea that MDMA-induced 
increases of 5HT delay the acquisition of MDMA self-administration. If this is the 
case, the inhibitory effect must be overcome for MDMA self-administration to 
progress. It has been hypothesised that repeated exposure to MDMA during initial 
self-administration sessions produces deficits in 5HT neurotransmission, thereby 
disinhibiting DA neurotransmission, and increasing the reinforcing efficacy of 
MDMA (Schenk, 2011). Some data support this idea. Following self-administration 
of about 100 mg/kg MDMA across 20 sessions, the MDMA-produced 5HT response 
was decreased, but DA was unchanged (Reveron et al., 2010). Following more 
extensive exposure to self-administered MDMA, however, the DA response became 
sensitised (Colussi-Mas et al., 2010). Accordingly, behavioural responses to MDMA 
following MDMA self-administration should reflect these changes: 5HT-mediated 
behaviours should be reduced and DA-mediated behaviours should be increased.  
A distinctive behavioural response to increased synaptic 5HT is the so-called 
‘5HT syndrome’. This repertoire of behaviours includes head weaving, fore-limb 
treading, and low body posture. Administration of the 5HT precursor, 5-
hydroxytryptamine (5-HTP), produced these behavioural effects that were then 
enhanced by co-administering an MAO inhibitor that decreased 5HT metabolism 
(Bogdanski, Weissbach, & Udenfriend, 1958; Page, 1958; Shore & Brodie, 1958). 
Subsequent research showed that a number of non-selective 5HT agonists produced 
the 5HT syndrome. The majority of the behaviours that comprise the 5HT syndrome 
have been attributed to 5HT1A, 5HT2A and 5HT2C receptor mechanisms (for a review, 
see Haberzettl, Bert, Fink, & Fox, 2013).  
One behavioural correlate of increased synaptic DA is stimulated horizontal 
activity (hyperlocomotion). Local infusions of DA, but not 5HT or NE, into terminals 
of the mesolimbic DA system increased forward locomotion (Pijnenburg, Honig, Van 
der Heyden, & Van Rossum, 1976). A wealth of data has subsequently shown similar 
effects following administration of DA agonists, and these effects are blocked by 
neurotoxic 6-OHDA lesions in the mesolimbic DA system (for example, Kelly & 
Iversen, 1976) and by DA antagonists (Pijnenburg et al., 1976; Pijnenburg, Honig, & 
Van Rossum, 1975). Repeated exposure to MDMA (Ball, Budreau, & Rebec, 2006; 
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Ball, Klein, Plocinski, & Slack, 2011; Ball, Wellman, Fortenberry, & Rebec, 2009; 
Ball, Wellman, Miller, & Rebec, 2010; Bradbury, Gittings, & Schenk, 2012; 
Colussi‐Mas & Schenk, 2008; Kalivas et al., 1998; Lettfuss, Seeger-Armbruster, & 
von Ameln-Mayerhofer, 2013; Ludwig, Mihov, & Schwarting, 2008; McCreary, 
Bankson, & Cunningham, 1999; Modi, Yang, Swann, & Dafny, 2006), produced an 
augmented horizontal activity response following some dosing regimens, 
corresponding with an enhanced DA response (Kalivas et al., 1993; Kalivas & 
Stewart, 1991; Sorg & Kalivas, 1991). Enhanced synaptic DA also underlies 
increased vertical activity (rearing), although relatively fewer investigations of the 
neurochemical underpinnings of this behaviour have been conducted. The responses 
were produced by DA agonists (Cornish & Kalivas, 2001; Costall, Eniojukan, & 
Naylor, 1982; Nordquist et al., 2008), and were blocked when extracellular DA was 
decreased by administration of administration of the endogenous neuropeptide, 
Nociceptin/Orphanin FQ (Vazquez-DeRose et al., 2013).  
In the current experiment, head-weaving, hyperlocomotion and rearing were 
measured either 5 or 14 days after MDMA self-administration. These time periods 
were chosen based on findings that MDMA self-administration produced 5HT deficits 
after 5, but not14, days of abstinence (Do & Schenk, 2011). A potential complication 
is that behavioural measurements can sometimes be difficult to interpret because of 
competing behaviours produced by some doses of drugs. For example, the dose-effect 
curve for horizontal activity produced by psychostimulants is in the shape of an 
inverted “U”. The ascending limb of the curve reflects dose-dependent increases of 
horizontal activity with low doses of drug. Following administration of higher doses, 
however, horizontal activity declines as psychostimulant-produced behaviour 
becomes dominated by repetitive stereotyped behaviour (Flagel & Robinson, 2007; 
Randrup & Munkvad, 1967). An increase in the dose of psychostimulant could 
therefore result in either an increase or decrease in horizontal behaviour. In addition, 
previous research has described difficulty in measuring 5HT syndrome during the 
simultaneous expression of other behaviours (Curzon, Fernando, & Lees, 1979). In an 
effort to negate these potential confounds, three different measures of 
hyperlocomotion will be recorded, and the time course of all behaviours will be 
analysed. 
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Method 
 
Experimental Overview 
 
 
 
 
 
 
 
 
 
 
Pilot Studies 
To find the dose of MDMA needed to induce 5HT syndrome, and to deduce a 
method to measure 5HT syndrome behaviours, a series of pilot studies were 
undertaken. Rats with varying drug histories were injected with 5.0 mg/kg (n=3) or 
10.0 mg/kg  (n=4) MDMA and videoed for 60 minutes. The videos were watched by 
multiple people and the head-weaving, fore-paw treading and low body posture were 
identified. It became obvious that the 10.0 mg/kg MDMA dose was required to induce 
5HT syndrome.  
 
Self-administration Testing 
For these groups, the dose of MDMA was decreased to 0.5 mg/kg/ infusion 
following the initial acquisition period. Testing continued until a total intake of 165 
mg/kg was reached (an additional 150 infusions), because previous research showed 
this dose of self-administered MDMA produced tissue deficits in 5HT. Each rat in the 
vehicle self-administration group (n=9) was matched to an MDMA self-administering 
rat. Behavioural testing was conducted after 5 days (5D; n=8) or 14 days (14D; n=8) 
of abstinence following the last self-administration session for the MDMA group, and 
14 days of abstinence following the last self-administration session for the vehicle 
(Control) group.  
 
Hyperlocomotion, 
head-weaving and 
rearing are 
measured 
following MDMA 
(10.0 mg/kg)  
Self-administration 
testing commences  
Catheter surgery  
Day x + 6 
or 
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testing ceases once 
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Day 0 Day x 
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Behavioural Testing 
Apparatus 
A single clear Plexiglas chamber (Med Associates Inc, USA; model ENV-
515) measuring 42 × 42 × 30 cm, set in a sound-attenuating box, was used to measure 
the behaviours. Four sets of 16 infra-red sensors spaced evenly 2.5 cm above the floor 
on each side of the box produced a lattice of beams that created squares of dimension 
25 × 25 mm. One forward locomotor count was recorded following the sequential 
interruption of 3 beams, which equates to the approximate size of the body of the rat. 
The number of locomotor counts produced, and the time (sec) spent in forward 
locomotion, were determined. The average velocity of forward locomotion (cm 
travelled per second) was also measured. A second set of identical infra-red sensors 
located 14cm above the floor of the chamber measured rearing counts.  
A camera was mounted on the ceiling of the sound-attenuating box to record 
head-weaving, fore-limb treading and low body posture. It became apparent after 
watching the videos, however, that the orientation of the camera only allowed the 
measurement of head-weaving- MDMA self-administration markedly altered the 
behaviours produced by 10.0 g/kg MDMA. The videos were then studied to derive a 
sound measurement system for head-weaving. Following extensive examination, it 
was decided that head-weaving was best measured by dividing the session into 5-
minute blocks and head weaving was measured for the first 60 seconds of each block. 
an ordinal scale of severity was decided on, as has been consistently used in previous 
research (Haberzettl et al., 2013; Jacobs, 1974a, 1974b). The head-weaving of every 
rat was quantified by one experimenter blind to the conditions. Measurement quality 
was checked by randomly assigning 3 videos each to 9 other experimenters. Previous 
studies have scored head-weaving using ordinal scales of severity. Head weaving was 
measured according to the following: 0- absent; 0.5- some signs of head weaving; 1- 
occasional head weaving; 1.5- frequent head weaving; 2- constant head weaving. 
A white noise generator masked extraneous noise. Prior to each test, chambers 
were wiped with Virkon ‘S’ disinfectant (Southern Veterinary Supplies, NZ). All 
experiments were conducted between 1300 and 1900 h in a temperature-controlled 
room (19°C) illuminated by red light. 
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Procedure 
Rats were habituated to the activity box for 30 minutes before the injection of 
MDMA (10.0 mg/kg; ip). The high dose of MDMA was chosen because a pilot study 
revealed that this dose evoked head-weaving most reliably. Forward locomotion, 
rearing and head-weaving were measured during the habituation period and for a 
further 45 minutes after MDMA administration.  
 
Statistical Analysis 
To measure the effect of MDMA administration on the behaviour of drug-
naïve animals, individual one-way ANOVAs were conducted for the all of the 
behaviours of the Control group produced during the eleven 5-minute time intervals 
between Time = -5, and Time = 45. Tukey post-hoc tests were used to identify the 
time-point(s) at which MDMA-produced behaviour significantly differed from that 
measured 5 minutes prior to MDMA administration (Time = -5). To determine the 
effects of abstinence, MDMA-produced behaviours were compared using separate 
repeated measures ANOVAs (Time X Group) for each of the behavioural measures. 
Main effects of Group or an interaction between Time and Group were further 
assessed using Tukey post-hoc tests. 
 
Results 
Control Group 
MDMA (10.0 mg/kg; i.p) administration caused an immediate head-weaving 
response, followed by hyperlocomotion. Figure 3.1 shows the time-course of head-
weaving for the control group during the habituation phase and after the 
administration of MDMA. The time-course exhibited an unusual pattern; pronounced 
head-weaving was produced during the initial and final portions of the session but not 
during the intervening time period. The decrease in the middle of the test session 
might reflect the emergence of competing behaviours. Indeed, forward 
hyperlocomotion gradually increased after MDMA administration (see Fig 3.2A; F 
(10, 88) = 10.27, p < 0.05) and was significantly increased from 15 minutes onward (p 
<0.05). Hyperlocomotion peaked about 25 minutes after MDMA administration and 
during this time head-weaving became more difficult to distinguish from generalised 
hyperactivity. Because head-weaving could only be confidently scored during the first 
20 minutes after MDMA, only these data were analysed. Head-weaving increased 
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with time (F (5, 48) = 5.23, p < 0.05) and was significantly increased 10 minutes after 
MDMA administration (p <0.05). 
Figure 3.2 shows the number of ambulatory counts (A), velocity of forward 
locomotion (B),  time spent in forward locomotion (C), and the number of rears (D) 
for the control group after administration of MDMA (10.0 mg/kg; i.p). The velocity of 
forward locomotion increased rapidly following MDMA administration (F (10, 88) = 
1.96, p < 0.05; Fig 3.2B) and was significantly increased during the first 5-minute 
interval (p < 0.05). The time spent in forward locomotion increased with time (F (10, 
88) = 13.73, p < 0.05; Fig 3.2C) and was significantly elevated from 10 minutes after 
MDMA (p <0.05). Rearing (Fig 3.2D) was higher prior to MDMA administration and 
was not increased subsequent to MDMA (F (10, 88) = 4.93, p < 0.05). 
 
 
Figure 3.1 displays Head-weaving for the Control group following vehicle self-administration. Rats were 
subjected to 14 days of abstinence prior to behavioural testing. MDMA (10.0 mg/kg; ip) was administered at 
Time= 0. * denotes p < 0.05 vs behaviour at Time = -5 minutes. 
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The effect of abstinence on behaviours 
There were no differences in the various responses during the 30 min 
habituation period. Thus, abstinence failed to alter the baseline levels of head-
Figure 3.2 displays Ambulatory Counts (A), Velocity of Forward Locomotion (B), Time Spent in Forward 
Locomotion (C), and Rearing (D) for the Control group following vehicle self-administration. Rats were 
subjected to 14 days of abstinence prior to behavioural testing. MDMA (10.0 mg/kg; ip) was administered at 
Time= 0. * denotes p < 0.05 vs behaviour at Time = -5 minutes. 
A B 
C D 
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weaving, various measures of forward locomotion, or rearing. The effect of 
abstinence on MDMA-produced responses depended on the behaviour.  
Table displays the The magnitude of MDMA-produced head-weaving was 
dependent on abstinence. A significant interaction was found for head-weaving (F 
(18, 207) = 1.90 p< 0.05). Head-weaving and was decreased 10 and 15 min following 
injection for the 5D (p<0.01), but not the 14D, group.  
Effects of abstinence on MDMA-produced hyperactivity depended on the 
measure. Time spent in forward locomotion was decreased following both abstinence 
periods, velocity was increased for both abstinence periods, and the number of 
ambulatory counts was unchanged as a result of abstinence.  Rearing was increased 
for both abstinence groups (p<0.01). 
 
Table 3.1: Statistical results from ANOVAs conducted on data from each of the behavioural responses to MDMA 
as a function of time and abstinence group(*=p<0.05, **=p<0.01, NS=not significant) 
 
 
 
 Head-
weaving 
Time 
locomotion 
Velocity Counts Rears 
Time F(9,207)=14.67 
** 
F(14,308)=57.0 
** 
F(14,308)=2.18 
** 
F(14,308)=54.2 
** 
F(14,308)=9.94 
** 
Group F(2,22)=2.4  
NS 
F(2,22)=4.031 
 * 
F(2,22)=7.537  
** 
F(2,22)=0.502  
NS 
F(2,22)=11.993 
** 
TimeXGroup F(18,207)=1.902 
* 
F(28,308)=2.20 
NS 
F(28,308)=1.232 
NS 
F(28,308)=1.24 
NS 
F(28,308)=3.09 
** 
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Figure 3.3 shows the behavioural responses to MDMA (10.0 mg/kg, IP) for control rats that had self-
administered vehicle and for rats that had self-administered MDMA. MDMA was administered at 
Time= 0. a  indicates a difference (p<0.05) between the 5 day abstinence group and control and b 
indicates a difference between the 14 day abstinence group and control (p<0.05). Symbols represent 
mean + SEM.. 
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Discussion 
This experiment was designed to compare behavioural correlates of 5HT 
(head-weaving) and DA neurotransmission (rearing and hyperlocomotion) for control 
rats and rats that had self-administered MDMA. In accordance with previous research 
(Spanos & Yamamoto, 1989), MDMA produced pronounced head-weaving in the 
control group. Head-weaving in the 5D abstinence group was significantly lower, 
suggesting a decrease in the 5HT response after MDMA self-administration, as has 
been suggested previously (Reveron et al., 2010). The results are consistent with 
previous research that showed a decrease in MDMA-produced 5HT syndrome 
following repeated experimenter-administered MDMA (Shankaran & Gudelsky, 
1999). The head-weaving for the 14D group was comparable to that of the control 
group, supporting the results of neurochemical analyses that also showed recovery of 
5HT (Do & Schenk, 2011). 
The length of abstinence required for recovery of 5HT following self-
administration was shorter than that reported by some other studies following 
experimenter-administered MDMA. This may be due to the different dosing regimens 
since the persistence of 5HT deficits were dose-dependent, with higher doses 
producing greater deficits (for example, Battaglia, Yeh, et al., 1988; Do & Schenk, 
2011; Insel et al., 1989). The dose of MDMA eventually self-administered in the 
current study was similar to, or greater than, some experimenter-administered doses 
of MDMA that showed more persistent 5HT deficits (for example, Battaglia, Brooks, 
et al., 1988; Sabol, Lew, Richards, Vosmer, & Seiden, 1996; Scanzello, 
Hatzidimitriou, Martello, Katz, & Ricaurte, 1993), but the frequency of dosing 
differed. The studies that used experimenter-administered MDMA injected 
consistently high daily doses of MDMA (10-80 mg/kg) for 4-5 days. In contrast, the 
daily dose of self-administered MDMA was initially low (about 3 mg/kg) and 
increased across test sessions (to about 15 mg/kg). Further, self-administration testing 
continued for a much longer period of time (about 30 days). These differences in 
frequency of dosing might account for the differences in time required for recovery of 
5HT deficits. The low dose of MDMA self-administered during initial test sessions 
might have produced a neuroprotective effect to the high doses of MDMA self-
administered during later test sessions. Indeed, previous research reported smaller 
MDMA-produced 5HT following pre-exposure to an intermittent dosing regimen of 
MDMA (Piper, Ali, Daniels, & Meyer, 2010). 
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It must be noted that the measurement of behavioural correlates of 5HT 
transmission was limited. The psychostimulant effects of MDMA produced 
behaviours that masked all of the behaviours (bar head-weaving) encompassed within 
5HT syndrome, rendering them unmeasurable. Thus only one behaviour, head-
weaving, was used as a measure of 5HT transmission. The measurement of 5HT 
neurotransmission in this experiment is therefore not ideal.  
MDMA did not produce rearing in the control group, as has been previously 
reported (O'Loinsigh, Boland, Kelly, & O'Boyle, 2001). Repeated exposure to self-
administered MDMA resulted in pronounced MDMA-produced rearing, as has also 
been reported previously (Lettfuss et al., 2013). Because rearing is a behavioural 
correlate of increased synaptic DA (Costall et al., 1982), the data are consistent with 
the ideas that acute MDMA produced a negligible DA response, and that repeated 
exposure to MDMA during self-administration enhanced the MDMA-produced DA 
response. The enhanced response is in accordance with one study that reported 
augmentation of the DA response produced by the same dose of MDMA (10.0 mg/kg) 
following self-administration of about 360 mg/kg MDMA (Colussi-Mas et al., 2010). 
Another study, however, reported no change in the MDMA-produced DA response 
following self-administration of about 100 mg/kg MDMA (Reveron et al., 2010). 
Thus, the enhanced DA response found following exposure during MDMA self-
administration appears to be dose-dependent.  
MDMA-produced rearing was also produced following 14 days of abstinence. 
This result is particularly interesting because it appears that the enhanced DA 
response was produced independent of 5HT deficits. Therefore, although there is 
evidence to suggest that the DA response produced by acute MDMA is modulated by 
5HT, repeated exposure to MDMA during self-administration appears to alter this 
relationship. This might be due to changes in specific receptor mechanisms following 
self-administration.  
It was expected that the enhanced DA response found following MDMA self-
administration would also be reflected in an enhanced hyperlocomotor response, as 
has been reported previously (Ball et al., 2006; Ball et al., 2011; Ball et al., 2009; Ball 
et al., 2010; Bradbury et al., 2012; Colussi‐Mas & Schenk, 2008; Kalivas et al., 1998; 
Lettfuss et al., 2013; Ludwig et al., 2008; McCreary et al., 1999; Modi et al., 2006), 
but the number of ambulatory counts produced by the self-administration and control 
groups was comparable. The MDMA self-administration groups exhibited a different 
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profile of horizontal locomotion, however: the velocity of forward hyperlocomotion 
was increased, and the time spent in forward locomotion was decreased. The number 
of ambulatory counts therefore did not reflect that MDMA self-administration altered 
MDMA-produced horizontal locomotion. The decreased time spent in forward 
locomotion combined with the increase in rearing, suggests that horizontal 
locomotion might have been limited by this competing behaviour. 
The complicated nature of the analysis of behavioural responses to 
psychostimulants has been addressed previously (Flagel & Robinson, 2007). In 
particular, high doses of psychostimulants produced stereotypy (Forster, Falcon, 
Miller, Heruc, & Blaha, 2002; Kuczenski & Segal, 1999; Nordquist et al., 2008) that 
interfered with the forward locomotion response. For example, low doses of AMPH 
produced hyperlocomotion throughout a test session. High doses of AMPH, however, 
produced stereotypy and therefore hyperlocomotion was restricted to the end of a test 
session, when stereotypy decreased (Kuczenski & Segal, 1999; Robinson & Becker, 
1986). The combination of the three measures of the hyperlocomotor response in the 
current study indicates that horizontal locomotion was similarly impacted. 
Alternatively, the high dose of MDMA used for behavioural testing may have 
produced a ceiling effect for the hyperlocomotor response. If this is the case, a lower 
dose of MDMA should allow the observation of group differences in the number of 
MDMA-produced ambulatory counts.  
The results show that exposure to MDMA during the acquisition of self-
administration decreased MDMA-produced head-weaving, a behavioural correlate of 
the 5HT response, and increased rearing, a behavioural correlate of the DA response. 
The results therefore support the idea that MDMA self-administration progresses as 
MDMA exposure produces deficits of the 5HT response and augmentation of the DA 
response. Serotonin deficits recovered with extended abstinence, as evidenced by the 
recovery of MDMA-produced head-weaving. Importantly, the enhanced rearing 
response was produced even following an abstinence period that produced recovery of 
the 5HT response. The two abstinence periods therefore provide a measure to 
investigate the roles of the 5HT and DA responses in the maintenance of MDMA self-
administration. If the 5HT response is critical to self-administration then responding 
should be decreased after 14, but not 5, days of abstinence. On the other hand, if an 
enhanced DA response is critical to self-administration, then responding should be 
comparable after both abstinence periods. 
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. 
Chapter 4 
Introduction 
The results from Chapter 3 showed that MDMA-produced head-weaving, a 
behavioural correlate of the 5HT response, was decreased 5, but not 14, days after 
self-administration. Further, a behavioural correlate of the MDMA-produced DA 
response, rearing, was only observed after rats had been exposed to MDMA self-
administration and this response persisted for at least 14 days following the last self-
administration session. Since neurochemical (Do & Schenk, 2011) and behavioural 
measures indicated a recovery of the 5HT response after 14 days, the sensitised DA 
response observed after 14 days following the last self-administration session cannot 
be attributed to continued disinhibition of DA resulting from reduced 5HT.  
Because, following MDMA self-administration, the MDMA-produced DA 
response was enhanced irrespective of the 5HT response, the inhibitory effect of 5HT 
on MDMA self-administration found during the acquisition phase might be reduced 
during the maintenance phase. Indeed, the progression of self-administration of other 
drugs of abuse has been attributed to sensitisation of the DA response resulting from 
repeated exposure (Vezina, 2004). The present study sought to determine whether 
5HT deficits impact responding maintained by MDMA. If so, then responding should 
be reduced following 14 days abstinence when 5HT responses had recovered. 
Alternatively, if a sensitised DA response maintains self-administration, as has been 
proposed for other drugs of abuse (Robinson & Berridge, 1993, 2001), then 
responding after either 5 or 14 days of abstinence should not differ.  
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Method 
 
Experimental Overview 
 
 
 
 
 
 
 
Self-administration Testing 
Rats underwent self-administration testing and, following acquisition, the dose 
of MDMA was decreased to 0.5 mg/kg/ infusion. Testing continued until a further 
150 infusions of this dose were self-administered (total self-administered = 165 
mg/kg). An abstinence period was then imposed for some groups before MDMA (0.5 
mg/kg/ infusion) self-administration resumed for 9 daily test sessions. For all tests 
responding was reinforced according to an FR1 schedule. One group was tested 
continuously and did not experience an abstinence period (0D; n=7); another group 
was subjected to 5 days of abstinence (5D; n=8); and a third group were subjected to 
14 days of abstinence (14D; n=10). The 0-day period represented the self-
administration protocol that is usually employed. The 5-day period was chosen 
because the results of Chapter 3 suggest that the MDMA-produced DA response was 
enhanced, and the 5HT response was reduced, after 5 days of abstinence. The 14-day 
period was chosen because the results of Chapter 3 suggest that the DA response to 
MDMA was augmented, and the 5HT response recovered, after 14 days of abstinence.  
 
Statistical Analysis 
Self-administration was compared following the various abstinence periods 
using a repeated-measures ANOVA (Group X Day) on the active lever responses 
produced during the 9 days of testing.   
 
MDMA (0.5 
mg/kg/ infusion) 
self-administration 
resumes for 9 test 
sessions 
Self-administration 
testing commences  
Catheter surgery  
Day x+1  
x+6 or 
x+15 
Day 4/5 
0- 5- or 14- day 
abstinence period 
commences once 
165 mg/kg is 
administered 
Day 0 Day x 
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Results 
Figure 4.1 shows the average number of responses as a function of group prior 
to the abstinence period, and during the 9 test sessions after the abstinence session for 
all groups. Pre-abstinence responding represents the average number of responses on 
the 3 days prior to the abstinence period. There was no effect of abstinence (F (2, 23) 
= 1.045, NS) or an interaction between days and group (F (16, 185) = 1.318, NS) on 
responding maintained by MDMA infusions. 
 
 
 
 
 
 
 
 
Discussion 
A previous study showed that tissue levels of 5HT were reduced 5 days, but 
not 14 days, following MDMA self-administration (Do & Schenk, 2011). In addition, 
the results from Chapter 3 showed that MDMA-produced head-weaving, a 
behavioural correlate of synaptic 5HT, was reduced 5 days, but not 14 days, after self-
administration. MDMA self-administration was therefore measured following 5 or 14 
days of abstinence. As expected, the self-administration profile of the 5D and 0D 
groups was comparable. However, the profile of self-administration for the 14D group 
Figure 4.1. Effects of abstinence on MDMA self-administration. The number of infusions self-
administered prior to the abstinence period is an average of the number of infusions self-administered 
during the 3 sessions prior to the abstinence period. Self-administration was measured for 9 days 
following either 0 (control) 5 or 14 days abstinence. Symbols represent mean number of responses 
during each daily 2 hr session  + SEM 
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was also similar to the 0D group. Thus, although there was recovery of the 5HT 
response following 14 days of abstinence, responding maintained by MDMA was 
unaltered. These findings suggest that 5HT does not impact the maintenance of 
MDMA self-administration.  
Recovery of 5HT function might have been expected to decrease responding 
maintained by MDMA because manipulations that increased synaptic 5HT attenuated 
responding maintained by a range of drugs of abuse. Reuptake inhibitors, the 
releasing stimulant, d-fen, and the 5-HT precursor, L-tryptophan, decreased AMPH 
(Porrino et al., 1989; F. L. Smith et al., 1986), METH (Munzar et al., 1999), COC 
(Carroll et al., 1990a, 1990b; Czoty et al., 2002; Howell & Byrd, 1995; A. McGregor 
et al., 1993; Negus et al., 2007; Porrino et al., 1989), heroin (Higgins et al., 1994; Y. 
Wang et al., 1995) and morphine (Raz & Berger, 2010) self-administration. The 
specific receptor mechanisms that underlie this inhibitory effect are not yet known. 
However, increased synaptic 5HT attenuated self-administration in a way that 
resembles the attenuation produced by DA antagonists, suggesting that this effect may 
be driven by 5HTergic inhibition of the DA response. A growing literature has 
described 5HTergic modulation of DA neurotransmission by a number of 5HT 
receptors (see Chapter 3), though the downstream effects of stimulation of these 5HT 
receptors are potentially very complex and, so far, poorly understood.  
The complexity of the 5HT-DA relationship is reflected by findings that 
stimulation of some 5HT receptors enhanced the MDMA-produced DA response. 
Agonists of the 5HT2A receptor enhanced MDMA-produced DA (Gudelsky et al., 
1994), and 5HT2A receptor antagonists decreased MDMA-produced DA (Nash, 1990; 
Schmidt et al., 1992; Schmidt et al., 1994; B. K. Yamamoto et al., 1995). Based on 
the idea that DA is critical to MDMA self-administration, antagonism of 5HT2A 
receptors would be expected to decrease MDMA self-administration. Indeed, the 
5HT2A antagonists, ketanserin and MDL100907, reduced responding maintained by 
MDMA in non-human primates (Fantegrossi et al., 2002). Another study reported that 
the 5HT1A agonist, 8-OHDPAT, abolished responding for MDMA in a single rat 
study (De La Garza II et al., 2007). The effects of stimulating 5HT1A receptors on DA 
are unknown, but the authors note that the highest dose of 8-OHDPAT inhibited 
motor behaviour. Therefore, the reduction in responding in this study could be 
attributed to a non-specific effect.  
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In light of the previous research, it might be surprising that the current results 
showed no effect of abstinence on MDMA self-administration. This discrepancy 
might be due to the magnitude of MDMA exposure in the current study, which has 
been associated with reduced extracellular and tissue 5HT (see Chapter 3; Do & 
Schenk, 2011; Reveron et al., 2010) that might reflect altered 5HT receptor 
mechanisms. The downstream effects of an increased 5HT response could therefore 
differ considerably in these rats. Perhaps more importantly, chronic exposure to self-
administered MDMA also enhanced the DA response (see Chapter 3; Colussi-Mas et 
al., 2010). It might be the case that the recovered 5HT response had no effect because 
this sensitised DA response becomes the critical determinant of responding 
maintained by MDMA. Indeed, the rearing response measured in Chapter 3 was not 
altered by the recovery of the 5HT response; probably because the critical determinant 
of rearing, the DA response, was enhanced. Since the DAergic response and self-
administration profiles following either abstinence period were comparable for both 
groups, it seems reasonable that the sensitised DA response mediates the maintenance 
of MDMA self-administration following abstinence. 
A substantial amount of literature supports the idea that enhanced DA 
responses underlie compulsive drug-taking and drug-seeking (see Robinson & 
Berridge, 1993, 2001). These ideas are based, in part, on the observation that  a 
sensitised DA response is found in neural pathways that have been associated with 
drug-produced reinforcement (Wise & Bozarth, 1987). Repeated intermittent 
exposure to a wide range of abused drugs enhanced DA neurotransmission, as shown 
by both behavioural and neurochemical measures (Vezina, 2004). A number of 
studies have reported behavioural sensitisation of locomotor-stimulating effects of 
MDMA following repeated experimenter-administered MDMA (Ball et al., 2006; 
Ball et al., 2011; Ball et al., 2009; Ball et al., 2010; Bradbury et al., 2012; 
Colussi‐Mas & Schenk, 2008; Kalivas et al., 1998; Lettfuss et al., 2013; Ludwig et al., 
2008; McCreary et al., 1999; Modi et al., 2006). Further, repeated exposure to 
experimenter-administered (Kalivas et al., 1998) or self-administered (Colussi-Mas et 
al., 2010) MDMA produced neurochemical sensitisation of extracellular DA. Direct 
support for the idea that an enhanced DA response underlies the maintenance of 
MDMA self-administration was found when both D1 and D2 receptor antagonists 
decreased self-administration (Brennan et al., 2009; Daniela et al., 2004; Shin et al., 
2008).  
64 
 
MDMA-seeking has also been attributed to enhanced DAergic mechanisms. 
The reinstatement paradigm is a model of relapse and craving which measures drug-
seeking behaviour in subjects with extensive self-administration experience, 
following a phase of forced abstinence/extinction. MDMA-seeking was reinstated by 
the DAT inhibitor, GBR 12909, the DA releaser, AMPH, and the D2 receptor agonist, 
quinpirole. Furthermore, both D1 and D2 receptor antagonists decreased MDMA-
seeking (Schenk et al., 2011). MDMA-seeking was not, however, reinstated by the 
SERT inhibitor, clomipramine, the 5HT2A agonist, DOI, or the 5HT2C agonist, mCPP 
(Schenk et al., 2011). The research therefore suggests that DAergic, but not 5HTergic, 
mechanisms underlie MDMA-seeking and further supports the idea that the DA 
response is critical to MDMA self-administration.  
It is possible that responding maintained by MDMA was not altered by 
abstinence because of an increased susceptibility to the reoccurrence of 5HT deficits.  
Responding was measured after 14 days of abstinence because the results from 
Chapter 3 suggested that the MDMA-produced 5HT response had recovered after this 
period. That is, MDMA-produced head-weaving, a behavioural correlate of synaptic 
5HT, was comparable to that produced by drug-naïve rats. Head-weaving was 
measured, however, in response to only one administration of MDMA. In the current 
experiment, the response to MDMA was measured following multiple doses of 
MDMA across multiple days, and thus it might be the case that repeated exposure to 
self-administered MDMA reproduced pre-abstinence 5HT deficits. There are two 
observations that suggest this explanation is unlikely. First, responding maintained by 
MDMA was not inhibited on the first day of testing after abstinence when the 
MDMA-produced 5HT response had recovered. Second, previous research described 
a protective effect of pre-exposure to MDMA when 5HT deficits produced by 
subsequent MDMA were measured. Deficits of tissue levels of 5HT and SERT 
produced by a binge dose of MDMA were reduced by previous exposure to repeated 
intermittent high doses of MDMA (Bhide, Lipton, Cunningham, Yamamoto, & 
Gudelsky, 2009; Piper et al., 2010).  
It must also be noted that the recovered 5HT response might have altered 
responding maintained by other doses of MDMA. To test this, a future study should 
measure responding for a range of MDMA doses following abstinence.  
While it appears that the MDMA-produced 5HT response is an important 
factor during the acquisition of self-administration (see Chapters 1 and 2), findings 
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from the current experiment suggest that the 5HT response might not play an 
important role once self-administration has been acquired. Instead, the data support 
the idea that sensitisation of the DA response underlies the maintenance of MDMA 
self-administration. 
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General Discussion 
There is a general conception amongst laypeople and researchers that MDMA 
is a drug with low abuse liability, and that use poses minimal harm. Recent data, 
however, suggest otherwise. Surveys indicate that some users become dependent and 
that dependence is associated with increased frequency of use, greater consumption 
on each occasion and tolerance to some of the behavioural effects (for example, 
Degenhardt et al., 2004; Degenhardt et al., 2009). There is now a substantial data base 
indicating that MDMA use compromises 5HT neurotransmission and also leads to 
persistent behavioural and cognitive deficits. 
The pharmacology of MDMA is not, however, consistent with a drug of 
abuse. Virtually all other drugs of abuse preferentially increase synaptic levels of DA 
but MDMA preferentially increases 5HT, and increases in DA are relatively small. 
Resolution of this paradox has focussed on changes in MDMA pharmacology 
following repeated exposure. It has been shown that repeated exposure decreases 
MDMA-produced 5HT responses (Reveron et al., 2010) and it has been suggested 
that this decrease disinhibits the DA response, making MDMA comparable to other 
drugs of abuse (Schenk, 2011). There have been limited data to address this intriguing 
hypothesis. The present thesis was, therefore, undertaken to more fully investigate the 
role of 5HT in the acquisition and maintenance of MDMA self-administration and to 
assess the idea that 5HTergic responses limit initial acquisition of self-administration 
but that continued drug taking becomes dependent on DAergic substrates. 
Unlike other drugs of abuse, the latency to acquisition of MDMA self-
administration was not dose-dependent (Schenk et al., 2007), acquisition criteria were 
achieved in a relatively small percentage of rats subjects and when these criteria were 
met the latency was relatively long (Schenk et al., 2012). Chapter 1 was designed to 
determine whether some of these differences might be attributed to the substantial 
5HT response to initial MDMA exposure.  
The MDMA-induced increase in extracellular 5HT was smaller for the group 
that subsequently acquired MDMA self-administration supporting the idea that 5HT 
limits the acquisition of MDMA self-administration. Somewhat surprisingly, the 
MDMA-produced DA response was not related to the initial response to the 
reinforcing effects of MDMA. This was unexpected because a wealth of data has 
shown that self-administration of other drugs of abuse is dependent on DAergic 
mechanisms (Vezina, 2004). Thus the mechanisms underlying this aspect of MDMA 
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self-administration appear to differ considerably from other drugs of abuse. The role 
of 5HT in the acquisition of MDMA self-administration was further investigated in 
Chapter 2 by examining effects of widespread 5HT depletion produced by a 
neurotoxic 5, 7-DHT lesion. Following this lesion, 100% of rats tested met an 
acquisition criterion for MDMA self-administration. This result is striking because 
MDMA self-administration is usually acquired by only about 50% of subjects. The 
marked increase in the proportion of subjects that acquired MDMA self-
administration complements the correlational study that suggests a role of 5HT in the 
acquisition of MDMA self-administration and provides experimental data indicating 
that 5HT is inhibitory to the acquisition of MDMA self-administration.  
Rats with a lower propensity to self-administer MDMA might therefore 
exhibit a distinctive phenotype. Specifically, MDMA-produced 5HT syndrome should 
be greater in rats with a lower propensity to self-administer MDMA. This idea could 
be explored by measuring MDMA-produced behaviours such as head-weaving and 
low body posture prior to the commencement of MDMA self-administration. 
With continued exposure to MDMA, 5HT neurotransmission becomes 
compromised; tissue levels of 5HT (Do & Schenk, 2011), SERT binding (Schenk et 
al., 2007) and MDMA-produced increase in 5HT overflow (Reveron et al., 2010) 
were decreased following self-administration. Because the previous studies showed 
that 5HT limits MDMA self-administration, it is reasonable to suggest that self-
administration progresses as a result of these decreased 5HT responses. If so, it was 
hypothesised that this decreased response might “permit” the expression of a more 
prominent DA response.  
In order to assess these possibilities, behavioural responses to MDMA were 
measured following self-administration in Chapter 3. In particular, behavioural 
measures of 5HT (head weaving) and DA (forward locomotion and rearing) activation 
were obtained. Repeated exposure to MDMA during self-administration produced 
transient deficits in the MDMA-produced 5HT response that were apparent 5, but not 
14, days following the last self-administration session. The time course of recovery is 
consistent with a previous study that showed deficits and recovery of tissue levels of 
5HT following MDMA self-administration (Do & Schenk, 2011).  
A novel and important result was that MDMA self-administration increased 
the DA response of rearing, consistent with  the enhanced DA overflow that had been 
reported following MDMA self-administration in another study (Colussi-Mas et al., 
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2010). In contrast to the transient nature of the decreased 5HT response, the sensitised 
DA response was persistent. These data suggest that the effects of MDMA on 5HT 
and DA are dissociable. It is possible, however, that alterations of 5HT receptor 
mechanisms might persist and that these alterations might modulate DA responses. 
There are at least 14 different 5HT receptor subtypes from 7 different families but 
only some of these receptors have been linked to DA.  
The majority of research on 5HT modulation of DA has focussed on the 
5HT1A, 5HT1B, 5HT2A and 5HT2C receptors, as these receptors have been located on a 
number of projections that innervate the mesocorticolimbic DA pathway. 
Investigations of the specific 5HT receptor mechanisms that modulate the acute 
MDMA-produced DA response have addressed the role of 5HT2A and 5HT2C 
receptors. The selective 5HT2A receptor antagonist, MDL 100907, and the 5HT2A/2C 
receptor antagonists, ritanserin and ketanserin, blocked the increase in DA produced 
by MDMA (Nash, 1990; Schmidt et al., 1992; Schmidt et al., 1994; B. K. Yamamoto 
et al., 1995) and 5HT2A receptor agonists enhanced the MDMA-produced DA 
response (Gudelsky et al., 1994). Following MDMA self-administration, however, the 
decreased influence of 5HT on DA suggests that 5HT2A receptor modulation of the 
MDMA-produced DA response might be reduced.  
All investigations of the effects of repeated MDMA on 5HT receptors have 
used experimenter-administered MDMA. Further, the majority employed high-
frequency regimens of high doses of MDMA. Thus it is difficult to conjecture how 
the alterations of 5HT receptors in these studies might compare with the effects of 
self-administered MDMA in the current study.  
A small number of studies have investigated the effect of repeated MDMA on 
the 5HT2A receptor, and some results suggest that that a down-regulation of the 
receptor is produced. A regimen of repeated MDMA that resulted in the 
administration of a total dose similar to that of the current study decreased 5HT 
levels, but did not produce a change in hippocampal 5HT2A mRNA 14 days later 
(Yau, Kelly, Sharkey, & Seckl, 1994) or alter head-twitching or locomotion produced 
by the 5HT2A receptor agonist, DOI (Granoff & Ashby Jr, 1997). A handful of studies 
reported alterations of the 5HT2A receptor after a moderate dose of MDMA. Repeated 
MDMA produced small decreases in 5HT levels and a widespread decrease of 5HT2A 
receptor density (I. McGregor et al., 2003). There are data to suggest that alterations 
of 5HT2A receptor density produced by repeated MDMA are related to the magnitude 
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of 5HT depletion. The recovery of 5HT2A receptor density was correlated with the 
extent of 5HT depletion (Reneman et al., 2002). Moderate doses of repeated MDMA 
also decreased function of 5HT2A receptor mechanisms. Nearly 2 months after 
MDMA DOI-produced anxiogenic effects and wet-dog shakes were decreased, 
showing persistent down regulation of 5HT2A receptor mechanisms (Bull, Hutson, & 
Fone, 2004). Interestingly, the same regimen of MDMA resulted in an increase of 
DOI-induced glucose utilization in the NAc. This result suggests that, following 
repeated MDMA, stimulation of 5HT2A receptors produced increased neuronal 
activity (Bull, Porkess, Rigby, Hutson, & Fone, 2006). 
Two studies measured MDMA-produced alterations of the 5HT2A receptor 
following intermittent dosing regimens. The frequency of dosing in these studies also 
differed markedly from that of the current study, in that MDMA was administered 
only every 5th or 7th day. A regimen of MDMA that administered a total dose of 60 
mg/kg produced a decrease in 5HT2A receptor mRNA (Kindlundh-Högberg, 
Svenningsson, & Schiöth, 2006). A higher dose of MDMA (total dose 120 mg/kg) 
produced increased behavioural and endocrine responses to DOI, but did not alter 
5HT2A/2C receptor density (Biezonski, Courtemanche, Hong, Piper, & Meyer, 2009). 
Thus the function of 5HT2A receptors appears to have been enhanced by this regimen. 
In monkeys, a moderate dose of repeated MDMA that decreased 5HT levels 
produced a trend of increased sensitivity to the 5HT2A/2C receptor antagonist, 
ketanserin, (Taffe et al., 2002). This finding, therefore, contrasts to those reported in 
rats. Similarly, increased functional activity of 5HT2A receptors was found following 
repeated exposure to MDMA in mice (Varela, Brea, Loza, Maldonado, & Robledo, 
2011). The relevance of this finding to self-administered MDMA in rats must be 
interpreted cautiously, however, because repeated MDMA does not produce 5HTergic 
deficits in mice (Stone, Hanson, et al., 1987). 
The aforementioned research reported equivocal results. In addition, relating 
the data to the current study is made more difficult by the markedly different dosing 
regimens used. Furthermore, the results of studies that used DOI or ketanserin must 
be interpreted cautiously due to the compounds’ affinity for 5HT2C receptors in 
addition to 5HT2A receptors. Irrespective of these issues, however, there are some data 
that show decreased function of 5HT2A receptor mechanisms following repeated 
MDMA. Because stimulation of 5HT2A receptors has been associated with increased 
synaptic DA, and because the DA response is enhanced following MDMA self-
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administration, the data do not support the idea that the decreased influence of 5HT 
on the MDMA-produced DA response is due to alterations of 5HT2A receptor 
mechanisms.  
In contrast to the 5HT2A receptor, systemic administration of the 5HT2C 
receptor agonist, Ro60-0175, dose-dependently decreased the basal firing rate of VTA 
DA neurons (Gobert et al., 2000) and decreased extracellular levels of DA in the 
NAc, FC and striatum (De Deurwaerdère, Navailles, Berg, Clarke, & Spampinato, 
2004; Gobert et al., 2000; Ji et al., 2006). Systemic administration of the 5HT2C 
receptor inverse agonist, SB 206553, or the antagonist, SB 242, 084, dose-
dependently increased the basal firing rate of VTA and substantia nigra DA neurons, 
increased burst activity in the NAc (Di Giovanni et al., 1999; Gobert et al., 2000), and 
increased basal levels of extracellular levels of DA in the PFC, NAc and striatum (Di 
Giovanni et al., 1999; Gobert et al., 2000). The decreased influence of 5HT 
modulation of the MDMA-produced DA response following MDMA self-
administration might therefore be due to downregulation of this receptor subtype. 
Few studies have investigated the effect of repeated MDMA on 5HT2C 
receptor mechanisms. Following repeated MDMA the inhibitory effect of the dual D1 
receptor antagonist/ 5HT2C receptor agonist, SCH 23390, on MDMA-produced 
hyperlocomotion was enhanced. A subsequent investigation showed this effect to be 
due to 5HT2C receptor mechanisms in the PFC, suggesting that repeated MDMA 
induced an enhancement of 5HT2C receptor function (Ramos, Goñi-Allo, & Aguirre, 
2004, 2005). Lower doses of repeated MDMA that decreased 5HT levels, however, 
did not alter hyperlocomotor or anxiogenic response to the 5HT2C receptor agonist, 
mCPP (Bull, Hutson, & Fone, 2003; Jones, Brennan, Colussi‐Mas, & Schenk, 2010). 
It must be noted that receptor function was tested 2 (Jones et al., 2010) or 3 (Bull et 
al., 2003) weeks after the final MDMA administration, and therefore any MDMA-
produced alteration of 5HT2C receptor function might have recovered during 
abstinence. In the one study that intermittently administered MDMA (every 7th day), 
5HT2C mRNA was dose-dependently increased (Kindlundh-Högberg et al., 2006). In 
monkeys, repeated high-dose MDMA that decreased 5HT levels produced increased 
sensitivity to the 5HT2C agonist, mCPP, in sustained attention tasks and progressive 
ratio responding (Taffe et al., 2002). The data suggest that repeated MDMA might 
induce an enhancement of 5HT2C receptor mechanisms. Because stimulation of 5HT2C 
receptor mechanisms has been associated with decreased DA neurotransmission, 
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enhancement of the 5HT2C receptor would not support the idea that alterations of this 
receptor subtype underlie the decrease in influence of 5HT on the MDMA-produced 
DA response found following MDMA self-administration. 
The 5HT1A receptor is found pre-synaptically on cell bodies of 5HT neurons 
where they regulate 5HT synthesis (Hamon et al., 1988; Neckers, Neff, & Wyatt, 
1979). Previous research failed to observe changes in 5HT1A autoreceptor 
mechanisms following MDMA exposure (Schenk, Abraham, Aronsen, Colussi-Mas, 
& Do, 2013). Post-synaptic 5HT1A heteroceptors are localised on mesolimbic DA 
projections (Doherty & Pickel, 2001) and are therefore well-placed to modulate DA 
neurotransmission. Systemic administration of a high, post-synaptic receptor-
stimulating, dose of the 5HT1A agonist, 8-OH-DPAT, increased extracellular levels of 
DA in the PFC (Assié, Ravailhe, Faucillon, & Newman-Tancredi, 2005), but 
decreased activity of DA neurons in the VTA (Arborelius et al., 1993).  
Repeated administration of high doses of MDMA produced region-dependent 
alterations of 5HT1A receptor density. Density was increased in the FC, but decreased 
in the hippocampus, 7 days after the last MDMA exposure. Furthermore, the density 
of 5HT1A receptors was positively correlated with 5HT1A mRNA levels (Aguirre, 
Frechilla, García‐Osta, Lasheras, & Del Río, 1997; Aguirre, Galbete, Lasheras, & Del 
Río, 1995). The same dosing regimen increased 8-OH DPAT-produced hyperthermia, 
which was correlated with the increase in 5HT1A receptor density in the FC (Aguirre, 
Ballaz, Lasheras, & Del Rıo, 1998). In monkeys, a high-dose regimen of MDMA also 
increased sensitivity to 8-OH-DPAT in a progressive ratio task (Taffe et al., 2002).  
It appears that a moderate dose of repeated MDMA does not alter 5HT1A 
receptors. Hippocampal 5HT1A mRNA levels were unchanged (Yau et al., 1994), and 
8-OH DPAT-produced hyperthermia (McNamara, Kelly, & Leonard, 1995), social 
interaction (M. R. Thompson, Callaghan, Hunt, & McGregor, 2008) and increases of 
extracellular acetylcholine in the FC (Nair & Gudelsky, 2006), were not altered. One 
study, however, reported decreased 8-OH DPAT-produced fore-paw treading after an 
abstinence period, suggesting down-regulation of 5HT1A receptor mechanisms 
(Granoff & Ashby Jr, 2001). A regimen of intermittent MDMA did not alter 5HT1A 
receptor density (I. McGregor et al., 2003; Piper, Vu, Safain, Oliver, & Meyer, 2006), 
5HT1A receptor mRNA levels (Kindlundh-Högberg et al., 2006) or 8-OH DPAT-
produced hyperthermia (Piper et al., 2006), but did decrease 8-OH DPAT-produced 5-
HT syndrome (Piper et al., 2006). The varying effect of the MDMA pre-treatment on 
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behavioural responses to 8-OH DPAT might be due to the different behavioural 
responses reflecting regional differences in MDMA-produced alterations of the 
5HT1A receptor. 
The data suggest that repeated MDMA only alters 5HT1A receptor function 
following administration of high doses. A total dose of MDMA that was similar to 
that self-administered in the current study (160 mg/kg), produced tolerance to the 
behavioural effects of 8-OH DPAT following abstinence (Granoff & Ashby Jr, 2001). 
It is possible, therefore, that the self-administered MDMA in the current study 
produced a similar effect. Because stimulation of post-synaptic 5HT1A receptors has 
been associated with reduced function of VTA DA neurons, such an alteration of 
5HT1A receptor mechanisms would support the idea that the decreased influence of 
5HT modulation on the MDMA-produced DA response after MDMA self-
administration was due to changes of specific 5HT receptor mechanisms. 
The 5HT1B receptor is located on pre-synaptic 5HT neurons, where it acts as 
an autoreceptor that controls 5HT release, and post-synaptically where it is a 
heteroceptor that modulates the release of other neurotransmitters (Bruinvels et al., 
1994; Sari et al., 1999). Post-synaptic 5HT1B heteroceptors are localised on inhibitory 
gamma- aminobutyric acid (GABA) projections from the NAc to the VTA, and on 
excitatory glutamatergic projections from the PFC to the NAc. Stimulation of 5HT1B 
receptors on GABA neurons inhibits release and thus disinhibits mesolimbic DA. 
Stimulation of these receptors might therefore be expected to enhance self-
administration. Stimulation of 5HT1B receptors on glutamatergic terminals decreases 
release of glutamate and DA, and therefore might be expected to decrease self-
administration since self-administration has been attributed to increases of synaptic 
DA (for a review, see Sari, 2004). The downstream effects of stimulating 5HT1B 
receptors are complicated and depend on the functional balance of stimulating both 
autoreceptor and post-synaptic heteroceptor populations.  
The effect of repeated MDMA on 5HT1B receptor mechanisms appears to be 
dependent on the dose and/ or the frequency of administrations. A high-frequency 
regimen of a moderate dose of MDMA produced tolerance to the locomotor-
activating effects of MDMA and the 5HT1B/1A receptor agonist, RU24969 (Callaway 
& Geyer, 1992). A lower dose of MDMA, however, induced behavioural sensitisation 
and enhanced the hyperlocomotor response to RU24969 (McCreary et al., 1999). It is 
not known how self-administered MDMA might alter the function of post-synaptic 
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5HT1B receptors. However, because behavioural sensitisation, rather than tolerance, 
was found following self-administration, it might be expected that enhancement of 
5HT1B receptor mechanisms would occur, akin to the results of McCreary et al. 
(1999). That behavioural sensitisation, a behavioural correlate of an enhanced DA 
response, was accompanied by sensitised 5HT1B receptor mechanisms supports the 
idea that the decreased modulatory effect of 5HT on the MDMA-produced DA 
response is due to alterations of 5HT receptors. 
The available data support the idea that changes in either 5HT1A or 5HT1B 
hetereceptor mechanisms could account for the sensitised DA response. To 
investigate this idea further, the function of 5HT1A and 5HT1B receptor mechanisms 
should be measured following MDMA self-administration. One behavioural measure 
of 5HT1A receptor activation is reciprocal forepaw treading (Granoff & Ashby Jr, 
2001). Thus this response to the selective 5HT1A agonist, 8-OH-DPAT, would provide 
valuable information. A response to 5HT1B receptor agonists is adipsia (Aronsen, 
Webster, & Schenk, in press) as well as hyperlocomotion (McCreary et al., 1999) and 
so measurement of these behavioural responses would provide an indication of the 
status of these receptors following MDMA self-administration. 
The decreased influence of 5HT on the MDMA-produced DA response might 
be due to sensitised DA receptor mechanisms in addition to, or instead of, altered 5HT 
receptor mechanisms, as has been suggested as a mechanism underlying other drugs 
of abuse (for a review, see Vezina, 2004). Neurochemical and behavioural studies 
have shown that repeated MDMA induces an enhanced DA response (for example, 
Kalivas et al., 1998). There are data to suggest that this enhanced response is 
accompanied by sensitised D2 receptor mechanisms. Repeated exposure to MDMA 
induced sensitisation of the locomotor-stimulating effects of a subsequent 
administration of MDMA, that was accompanied by sensitisation of the behavioural 
effects of the D2 receptor agonist, quinpirole (Bradbury et al., 2012).  
Further, sensitised D2 receptor mechanisms appear to play a role in MDMA-
seeking. Compulsive drug-seeking has been attributed to sensitised DA mechanisms 
(for a review, see Robinson & Berridge, 1993, 2001). Following extensive MDMA 
self-administration, administration of the DAT inhibitor, GBR 12909, or the DA 
releaser, AMPH, induced MDMA-seeking. In addition, the D2 receptor agonist, 
quinpirole, but not the D1 receptor agonist, SKF 81297, produced MDMA-seeking 
(Schenk et al., 2011). Thus the data suggest that exposure to MDMA during self-
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administration produced an enhanced DA response that was accompanied by 
sensitised D2 receptor mechanisms and therefore support the idea that sensitisation of 
DA receptor mechanisms occurs independent of 5HT modulation. 
It would be of interest to obtain more direct measures of the effect of MDMA 
self-administration on MDMA-produced 5HT and DA responses using in vivo 
microdialysis. This was the original plan for the experiment of Chapter 3 and the 
study was initiated. The experiment could not be completed, however, due to 
equipment failure. The results of this study would be expected to reflect the data from 
Chapter 3. Augmented MDMA-induced increases of extracellular DA would be 
expected in the MDMA self-administration groups after either abstinence period. An 
attenuated MDMA-induced increase of extracellular 5HT would be expected 5 days, 
but not 14 days, following MDMA self-administration.  
The role of 5HT in the maintenance of MDMA self-administration was 
investigated in Chapter 4 by measuring responding in rats that had, or did not have, 
5HT deficits. Responding maintained by MDMA was comparable for the two groups, 
suggesting that following acquisition of self-administration 5HT deficits are not a 
critical determinant. An interesting study that would further determine the role of 5HT 
in the maintenance of MDMA self-administration could measure the effect of a 
neurotoxic 5, 7-DHT lesion following acquisition of self-administration. In fact this 
experiment was also part of the initial plan but in preliminary studies, a large 
percentage of the rats became ill and so the experiment was abandoned. A more 
reasonable approach might be to determine the effects of 5HT antagonists on MDMA 
self-administration. 
Taken together, the data support the idea that the DA response becomes 
critical to the maintenance of MDMA self-administration. This change in the critical 
determinant of MDMA self-administration from 5HT (acquisition) to DA 
(maintenance) might underlie the change in the profile of MDMA self-administration. 
Following extended testing, MDMA self-administration begins to share the 
characteristics of responding found with other psychostimulants. Responding 
increases, becomes dose-dependent (Schenk et al., 2012), and is attenuated by DA 
receptor antagonists (Brennan et al., 2009; Daniela et al., 2004). Further, after 
extended self-administration DAergic mechanisms induce MDMA-seeking (Schenk et 
al., 2011). Thus after using a range of experimental procedures to examine the role of 
5HT in MDMA self-administration, the data of this thesis suggest that, like other 
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drugs of abuse, MDMA self-administration is dependent on stimulation of DA 
neurotransmission.  
 
A future study could further investigate this by measuring responding 
maintained by MDMA following depletion of DA. In rats that have acquired MDMA 
self-administration, the DA neurotoxin, 6-OHDA, or vehicle could be infused 
centrally into the VTA to lesion mesolimbic DA neurons. Thereafter, responding 
maintained by MDMA could be measured. Attenuated or abolished responding would 
support the idea that the DAergic response is the critical determinant of the 
maintenance of MDMA self-administration. 
The findings of this thesis support the wealth of literature that suggests drug-produced 
reinforcement is mediated by DAergic mechanisms, and adds to the relatively small 
literature that describes a decrease in drug-produced reinforcement following an 
increased 5HT response. The findings of this thesis also suggest that the repeated use 
of ecstasy, of which MDMA is the active ingredient, could result in a sensitised 
DAergic system and thus lead to an increase in the reinforcing efficacy of ecstasy and 
other drugs of abuse. In addition, the findings suggest that this enhancement of the 
DAergic system is persistent, and therefore might lead to the experience of heightened 
sensitivity remaining for significant periods of time after last ecstasy use. 
Conclusions 
The susceptibility to acquire MDMA self-administration is dependent on the 
5HT response to initial MDMA, with the propensity to meet an acquisition criterion 
inversely related to the magnitude of the response. Repeated exposure to MDMA 
during self-administration produced a reduction of the 5HT response, and 
sensitisation of the DA response. The enhanced DA response is proposed to underlie 
the progression of MDMA self-administration. The progression of MDMA self-
administration therefore reflects a shift in the predominant neurochemical effect of 
MDMA from being 5HTergic to DAergic.  
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